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Human cytomegalovirus (HCMV) is a widespread human herpesvirus pathogen and 
prototypical member of the β-herpesvirus subfamily. Like all herpesviruses, the virus 
establishes a lifelong latent infection following host exposure, which has the potential to 
reactivate periodically and contribute to recurrent disease processes. In individuals with weak 
or compromised immune systems, such reactivation can lead to profound pathology. 
Understanding how latent infections are maintained is important for uncovering how HCMV 
causes disease. The study of viral genes that are expressed during latent infection grants 
insight into how latency is regulated and how it could be therapeutically targeted. To that end, 
this project has sought to evaluate the functional significance of one such viral gene termed 
LUNA in the context of latency. In models of experimental latent infection based on primary 
myeloid cells, levels of viral gene transcription were found to be significantly reduced 
following infection with LUNA deletion mutant viruses, consistent with corresponding 
observable changes in post-translational histone modifications over the viral promoters of 
latency-associated genes. Additionally, using luciferase reporter systems, latency-associated 
viral gene promoters became activated in response to the expression of wild-type LUNA. 
Together, these findings argue for a role of LUNA in regulating viral gene expression during 
latent HCMV infection. One possible mechanism by which LUNA may fulfil its role is by 
targeting cellular ND10 structures, known intrinsic inhibitors of herpesvirus gene expression, 
for disruption. In support of this, latently infected cells were found to be devoid of ND10, a 
phenotype that was recapitulated by the direct expression of wild-type LUNA. Furthermore, 
mutation studies confirmed the identification of a novel deSUMOylase activity encoded by 
LUNA that was responsible for mediating ND10 disruption. Use of a catalytically inactive 
LUNA mutant in transcriptional analyses of latent infection also generated similar results as 
with the LUNA deletion viruses. Overall, these data support the hypothesis that LUNA serves 
as an important regulator of viral gene expression during latency, which is likely linked to its 
ability to target ND10 structures for disruption, thus raising the possibility that inhibition of 
deSUMOylation may serve as a novel therapeutic strategy to target latent HCMV infection. 
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Evidence for the earliest known forms of herpesvirus infection can be traced as far back as 
the times of the Ancient Greeks, who coined the namesake “herpes” – from ἕρπειν (hérpein, 
“to creep”) – in likely reference to the spreading nature of herpetic skin lesions
1
. Yet, it 
would not be until 1893, when French scientist Emile Vidal specifically recognised the 
person-to-person transmission of herpesviruses (in his case, herpes simplex) that an entire 
field of virology, with its own broad ramifications, would come to be foreshadowed. Today, 
the herpesviruses comprise an extensive group of large DNA viruses that are ubiquitous in 
nature and responsible for causing a myriad of diseases, some far removed from the 
mucocutaneous conditions they once originally stood for.  
 
As illustrated in Figure 1.1, all herpesviruses share a distinctive virion architecture, 
consisting of a linear double-stranded DNA core surrounded by an icosahedral capsid, a 
tegument and a glycoprotein-containing envelope. In spite of this characteristic morphology, 
only recently has sequence data for herpesvirus genomes been instrumental in establishing a 
thorough taxonomy that now places three separate families, representing three major viral 
lineages, under the single principal order of Herpesvirales: Herpesviridae, Alloherpesviridae 
and Malacoherpesviridae
2
. These subdivisions closely mirror the phylogenetic branching 
order of their natural hosts; and thus, the Herpesviridae family contain viruses of higher 
vertebrates (namely mammals, birds or reptiles) while the Alloherpesviridae and 
Malacoherpesviridae families list viruses of amphibians and fish, or of bivalves, 
respectively. Notably, herpesviruses exhibit a remarkable degree of specificity, and it is 
typical for most to be restricted to a single host species. With more than 200 distinct 
herpesviruses identified to date – likely representing only a fraction of the total number that 
actually exists – the sheer diversity of their combined host repertoire is indicative of a long 



























The most intensely studied herpesviruses are members of the Herpesviridae family. This 
family is clustered into three major phylogenetic clades, which are taxonomically referred to 
as the Alphaherpesvirinae (α), Betaherpesvirinae (β) and Gammaherpesvirinae (γ) 
subfamilies. Each subfamily is divided into two or more genera; for instance, the 
Alphaherpesvirinae comprise the genera Simplexvirus and Varicellovirus. Among these 
subgroups are nine herpesviruses that have been identified in humans, constituting the       
so-called ‘human herpesviruses’ (Table 1.1). Extrapolation of evolutionary rates indicate that 
the α-herpesviruses separated from their parent lineage about 210 million years ago, before 
the lineage itself diverged approximately 30 million years later, giving rise to both the β- and 
γ-herpesviruses (Figure 1.2)
4
. Consistent with extensive evolutionary divergence, the human 
herpesviruses display a diverse range of biological properties, differing with respect to host 
cell range, length of replication cycle, and cytopathology. Though, one striking common 
feature is their ability to establish a latent infection and thereby persist for the lifetime of the 
infected host. While the mechanisms by which this is achieved vary across individual 










The general structure of the herpes virion consists of a linear double-stranded DNA core; an 
icosahedral capsid containing 162 capsomeres, including four protein subunits; the tegument, an 
amorphorus layer of phosphoproteins that is released into the host cell following infection; a 
lipid bilayer membrane envelope, which is derived from the trans-Golgi network of the host 
cell; and multiple glycoprotein complexes (at least 11) that are embedded in the lipid bilayer 
and which act as viral receptors. 
 
3 
Table 1.1 - Nomenclature of the human herpesviruses 
 
Taxonomic designation Common name Viral subfamily 
Human herpesvirus (HHV)-1 Herpes simplex virus 1 α-herpesvirus 
HHV-2 Herpes simplex virus 2 α-herpesvirus 
HHV-3 Varicella-zoster virus α-herpesvirus 
HHV-4 Epstein-Barr virus α-herpesvirus 
HHV-5 Human cytomegalovirus β-herpesvirus 
HHV-6 variant A or B HHV-6 variant A or B β-herpesvirus 
HHV-7 HHV-7 β-herpesvirus 

























     Figure 1.2 - Evolutionary timescale for the human herpesviruses  
A phylogenetic tree for selected human herpesviruses deduced by McGeoch et al. (1995) 
using amino acid sequences from several well-conserved genes. Subfamily groupings are 
indicated by Greek letters, with Herpes Simplex Virus (HSV)-1, HSV-2, and varicella zoster 
virus (VZV) representing the α-herpesviruses, HCMV and human herpesvirus 6 representing 
the β-herpesviruses, and Epstein-Barr virus (EBV) representing the γ-herpesviruses. The 
proposed timescale is shown in millions of years before present (M-years BP). The oldest part 
of the tree is shown as a broken line to indicate lower confidence in data for this region. 
Adapted from McGeoch et al. (1995) 
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1.2. HCMV: BASIC VIROLOGY 
 
Human cytomegalovirus (HCMV; also known as HHV-5) is one of the nine members of 
herpesvirus that infects humans. Along with its closest relatives, the roseoloviruses          
(HHV-6A, HHV-6B and HHV-7), HCMV belongs to the subfamily Betaherpesvirinae.        
The virus remains one of the best characterised members of this group and is often 
considered the prototypical β-herpesvirus, owing to its high host species specificity, 
distinctive cytopathology (cytomegaly), slow growth kinetics in culture, and in vivo tropism 
for haematopoietic tissue and salivary glands
5,6
. Since its isolation in 1956, the clinical 
presentation of HCMV disease has been widely catalogued and extended to include severe 
forms affecting both congenital and adult populations, wherein a limited control of viral 





1.2.1. Genome Structure, Organisation and Replication 
 
At the genomic level, HCMV is the largest of any human viral pathogen, possessing a linear 
double-stranded DNA molecule at approximately 235 kbp in size
8
. The organisation of the 
genome is complex and comprises two regions of unique sequence, termed unique long (UL) 
and unique short (US), which are separated by internal repeat sequences (IRL and IRS) and 
bounded by terminal repeat sequences (TRL and TRS) to yield the overall configuration: 5’–
 TRL – UL –IRL – IRS – US – TRS – 3’. Located between the UL57 and UL69 genes of the 
UL region is a cis-acting site that serves as the only known origin of lytic DNA replication 
(oriLyt), which also happens to be one of the largest among the Betaherpesvirinae
9,10
. Due to 
recombination events occurring naturally in replicating DNA, the inversion of the UL and US 
regions with respect to each other permits the HCMV genome to exist as one of four possible 
isomers; however, while this is dispensable for viral replication, the importance of viral 
genome isomerisation remains largely unknown.  
 
Determination of the genetic content of HCMV has been a protracted process, serving as a 
constant reminder of the unbridled complexity that surrounds the coding potential of the virus.  
Sequence annotation of the clinical (hitherto referred to as low-passage) strain Merlin, which 
has become the reference strain for wild-type HCMV, lists approximately 170 protein-coding 
open reading frames (ORFs) in addition to 39 herpesvirus ‘core’ genes
11
. The core genes, 
5 
which are orthologous across all members of the human herpesvirus family, chiefly encode 
proteins involved in viral DNA replication as well as structural components of the virion. The 
vast majority of remaining HCMV genes however, while dispensable for growth in vitro, are 
replete with important accessory functions, notably involved in evading host immune 
responses, mediating virus cell tropism, and regulating latency. These comprise several sets of 
genes – grouped into 15 gene families – that unsurprisingly share homology with other 
cellular genes and show conservation among other primate cytomegaloviruses (Figure 1.3). 
Nevertheless, despite this requisite genomic data, HCMV is increasingly being recognised as 
having a multifaceted transcriptome
12
. To this end, ribosome profiling has led to the 
suggestion that up to 604 additional protein-coding ORFs may exist, most of which are very 
short and located upstream of previously identified ORFs
13
. Moreover, the transcriptome has 
been linked to noncanonical translation events, such as the production of polyadenylated non-
coding RNAs, overlapping anti-sense transcripts, and also a variety of non-polyadenylated 
RNAs, such as microRNAs, many of whose roles are yet to be fully characterised, but appear 
to be regulatory
14,15
. Indeed, it is worth noting that efforts to establish an accepted reference 
strain were historically marred by the progressive realisation that diverse sequence variation 
occurs throughout HCMV genomes, restricting their global usage. Of particular note is that 
high-passaged (i.e. laboratory-derived) strains of HCMV – which were among the first to be 
sequenced – had been found to acquire significant mutations, deletions and rearrangements as 
a result of extensive adaptation to laboratory cell culture compared to low-passaged clinical 
isolates
16
. Naturally, the latter are used conventionally for research in an attempt to preserve 
the characteristics of wild type HCMV. Yet, the propensity for rapid mutation in HCMV is 
striking with instances of mutations being reported in even low-passaged strains, such as 
TB40/E exhibiting frame shift mutations in UL141 relative to the reference strain Merlin
17
. 
Nevertheless, several studies have since been able to demonstrate the presence of discrete 
clusters of polymorphism within a subset of HCMV genes, which has accordingly allowed 














































Figure 1.3 - Open reading frame arrangement of HCMV low-passage isolates  
Figure 3. Genome annotation of the low-passage (clinical) HCMV strain Merlin (GenBank 
accession number: NC_006273). The genome is visualised as a single line, with nucleotide 
positions given in bps. Terminal (TRL,TRS) and internal (IRL/IRS) repeat regions are indicated 
by white boxes. Genes are represented by arrows, with up to 15 colours assigned to individual 
gene families. Also represented by the figure are four large non-coding RNAs and the origin of 
lytic replication (OriLyt). Reproduced from Sijmons at al. (2014) under an open access license 
(CC-BY).  
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Table 1.2 - Properties of selected HCMV strains and their bacterial artificial 
chromosome (BAC) clones [Adapted from: Frascoli et al. Methods Mol Biol (2014)] 
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As with other herpesviruses, the life cycle of HCMV exhibits both latent and lytic / productive 
phases, each denoted by distinct patterns of viral gene expression
28
. During latency, viral gene 
expression is tightly controlled, with few but well-defined latency-associated transcripts 
(LATs) being expressed that do not coincide with production of infectious virions. By 
contrast, gene expression during lytic replication is extensive and unrestricted, following a 
temporally regulated cascade that culminates in the lysis of infected cells and the release of 
mature viral progeny. The products of these genes are assigned to one of three classes based 
upon their expression kinetics: immediately-early (IE), early (E) or late (L) (Figure 1.4). In 
brief, IE genes – which arise independently of de novo viral protein synthesis and are thus the 
first to be expressed – encode regulatory transactivating factors that are necessary to drive the 
viral-cell fate decision towards lytic replication
29
. The proceeding set of E genes, whose 
activation is dependent on prior IE gene expression, contribute towards essential processes 
such as viral DNA replication and repair as well as immune evasion. Encoded among these is 
a conserved set of six core replication proteins, namely: the viral DNA polymerase (UL54), 
the polymerase-associated processivity factor (UL44), the single-stranded DNA (ssDNA) 
binding protein (UL57), and the heterotrimeric helicase-primase complex formed by HP1 
(primase; UL105), HP2 (primase-associated factor; UL70) and HP3 (helicase; UL102)
30
. 
Finally, L genes, which are expressed following viral genome synthesis, are implicated in the 





















The process by which HCMV replicates its genome may be described in reference to its lytic 
replication cycle. Firstly, in order to gain entry into cells, incoming virus particles undergo 
multistep binding at the cell surface that results in membrane fusion and penetration
31
. This 
liberates nucleocapsids into the cytosol, along with several tegument proteins. The 
nucleocapsids are then transported to the nuclear pore complex along the host microtubule 
network, where uncoating of the viral DNA takes place
32
. Once released into the nucleus, the 
otherwise linear DNA rapidly (within 2 hours post infection) becomes circularised and 
interacts with host cell histone proteins to form nucleosomes that partially resemble cellular 
chromatin
33,34
. The resulting viral episomes serve as templates for virus transcription and 





Replication compartments develop adjacent to small subnuclear structures known as 
promyelocytic leukaemia bodies (PML-NBs) or nuclear domain 10 (ND10), and come to 
occupy large parts of the nuclear space at late times post infection
36,37
. Their formation and 
growth signify a dynamic reorganisation of the nuclear architecture that includes, for 
Figure 1.4 - Overview of HCMV lytic infection cycle  
a. Parental viral DNA enters the host 
cell nucleus and rapidly assumes a 
circular, episomal configuration. b. 
Viral immediate-early (IE) genes are 
the first to be expressed, the 
transcription of which arises in the 
absence of de novo virion production 
and involves a hijacking of host RNA 
polymerase II. c. IE proteins are 
transported into the nucleus and drive 
the next phase of early (E) gene 
expression, whose products include 
proteins required for viral DNA 
replication. d. DNA replication 
stimulates the expression of the late (L) 
genes, the majority of which encode 
viral structural proteins. e. + f. Virion 
capsid assembly and encapsidation of 
viral progeny take place in the nucleus. 
g. Virions egress from the nucleus and 
the cell, usually resulting in cell lysis. 
[Adapted from: Knipe et al. Nat Rev 
Microbiol (2008)] 
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instance, rearrangement of host cell nuclear proteins and partitioning of cellular chromatin, 
which, overall, help to concentrate factors and processes required for viral replication
35,38,39
. 
Notably, HCMV DNA synthesis has been found to occur at the periphery of replication 
compartments, with replicated DNA subsequently becoming localised to the interior of 
compartments
40
. At present, it is understood that HCMV genome replication is initiated at 
the oriLyt, and is dependent on a viral complex formed by UL84 and the key regulatory 
protein IE2
41,42
. In addition, four viral phosphoproteins encoded by UL112-113 (namely 
pp34, pp53, pp50 and pp84) become associated at pre-replicative sites – known structural 
precursors of replicative compartments – to coordinate assembly of the viral replisome
43
. 
This leads to the eventual recruitment of the aforementioned core replication proteins that 
participate in the synthesis of viral genomic DNA and which remain associated with the 
replication compartment throughout the entire infection
44
. Here, the helicase-primase 
complex unwinds the template DNA, thereby generating the primer from which the UL54-
UL44 complex will synthesise the leading strand, while UL57 enforces strand separation to 
prevent any unnecessary reannealment
45
. During this period, other HCMV accessory proteins 
as well as host cellular factors may come to be involved, such as viral deoxyribonuclease 
UL98, and host SWI/SNF family of chromatin remodelers, which in particular, are crucial 
for granting replication machinery access to compacted DNA
46,47
. Thus, as viral DNA 
synthesis proceeds, long head-to-tail concatemers containing the four genomic sequence 
isomers are produced, serving either as new templates for ongoing cycles of replication or 
targets of cleavage for viral assembly. In the case of the latter, a viral terminase complex 
composed of viral UL89, UL56 and UL51 is responsible for processing concatemeric DNA 
into unit-length molecules by cleaving at DNA packaging signals called pac1 and pac2
48,49
. 
These cis-acting sites are conserved among herpesvirus genomes and are crucial for viral 
DNA maturation
50,51
. While binding of UL56 to pac1 and pac2 appears to be important for 
initiating viral genome packaging, the mechanisms underlying subsequent encapsidation of 
nascent DNA into preformed capsids within the nucleus are not fully known
48,52
. Yet, it is 
clear that progeny HCMV genomes are stripped naked before being packaged, as mature 
linear DNA is devoid of any nucleosomes within the completed virus particle
53
. After 
nucleocapsids have been translocated from the nucleus, HCMV virions undergo maturation 
in the cytosol. In this regard, the essential processes of viral nuclear egress and 
morphogenesis remain poorly understood. One generally accepted view is that HCMV 
participates in two distinct envelopment processes; the first of which is transient to allow 
viral nucleocapsids to exit the nucleus, with the second being indefinite as virions bud into a 




1.2.2. Clinical pathogenesis of HCMV disease   
 
HCMV is epidemiologically prevalent, infecting approximately 60–100% of the global 
population depending on specific demographics, such as age, gender and socio-economic 
status
6
. Although the vast majority of HCMV infections are asymptomatic, populations most   
at-risk of pathology include the developing foetus, HIV-infected hosts, and recipients of bone 
marrow and solid-organ transplantation
56
. Together, these groups represent a significant source 
of morbidity and mortality worldwide for which HCMV serves as an important viral pathogen. 
 
In the clinic, HCMV may directly affect a diverse range of anatomical sites, with the lung, 
gastrointestinal tract, central nervous system and retina, among others, being linked to overt  
end-organ disease
57
. Here, the underlying pathology is widely believed to be driven by 
uncontrolled lytic viral replication that culminates in a clear, cytopathic effect
58
. In support of 
this, histological analysis of affected organs obtained from infected individuals typically 
reveals the presence of characteristic viral inclusions and necrotic damage. Moreover, the 
administration of antiviral therapy (e.g. ganciclovir) to patients with active viral replication 
and disease leads to a decrease in viral load and an improvement in symptomatology, which 
contrasts with use of steroids that can promote disease
59,60
. Interestingly, the frequency of 
particular disease presentations vary between different cohorts of patients with, for example, 
HCMV retinitis being more prevalent in the HIV/AIDS population, HCMV pneumonia 
manifesting after haematopoietic stem cell transplantation, and HCMV neurological sequelae, 
including sensorineural hearing loss, commonly exhibited by infected infants. However, 
HCMV infection has also come to be associated, albeit statistically, with other so-called 
indirect effects, such as cardiovascular disease and morbidities related to normal aging
61,62
. 
Although the possibility of attributing specific organ dysfunction to HCMV infection cannot 
be discounted in such cases, many studies have nonetheless sought to investigate the role of 
HCMV as a co-factor in their pathogenesis and less so an epiphenomenon. Notably, the 
potential contribution of HCMV towards immunopathology appears to be a common factor 
that links a number these particular disease associations
63
. Throughout its course as a lifelong 
persistent infection, for instance, it has been speculated that chronic immune surveillance for 
HCMV may generate an increased abundance of activated T cells that can mediate 
inflammatory attacks on bystander cells, such as the arteriolar endothelium
64,65
. Additionally, 
in elderly patients, a reduced number of naïve T cells would make seropositive people less 
able to respond sufficiently to vaccines, resulting in excess mortality during periods of 




As eluded to above, the immune status of the infected individual is a major determinant for the 
clinical expression of HCMV-associated disease, such that those with compromised immune 
systems are left especially vulnerable
57
. Early clinical data obtained from patients undergoing 
allografts showed that decreases in adaptive immune responses – brought about by the 
necessary administration of immunosuppressive drugs – were strongly linked to the 
development of clinically significant HCMV infection and invasive end-organ disease
66,67
. In 
this respect, the passive transfer of antiviral antibodies or in vitro expanded HCMV specific 
CD8
+
 T-cells was found to confer a protective effect in infected allograft recipients
68,69
. 
Similarly, HCMV is regarded as a common opportunistic infection in individuals living with 
HIV, particularly as CD4
+
 T cell counts fall below 100 cells/mm
3 70,71
. Given that 
antiretroviral therapy, which helps to maintain the CD4 count above 100, is regarded as an 
effective prophylactic strategy against HCMV disease, this further demonstrates how adaptive 
immune surveillance is important in controlling the virus. For the foetus and newborn infant, it 
has been suggested that the immaturity of the adaptive immune system present during that 
developmental period may explain their susceptibility to HCMV infection
72
. In support of this, 
the magnitude of the CD4
+
 T cell response in the foetus has been correlated against the 
severity of HCMV disease
73,74
. Additionally, during congenital HCMV infection, the number 
of HCMV specific CD4
+
 T cells are very low or undetectable in infants, and furthermore, are 
unable to effectively produce inflammatory cytokines, such as IFN-γ and IL-2
75
. 
Consequently, these factors are believed to negatively affect viral clearance, thereby 
increasing the risk of HCMV disease progression. 
 
Advances in next-generation sequencing (NGS) technologies have enabled the comprehensive 
study of genetic diversity across the entire HCMV genome and ongoing work has examined 
whether this may serve as an important HCMV virulence factor
76
. Longitudinal changes in the 
global HCMV population, for example, are known to contribute to host immune evasion. 
Differential properties conferred through polymorphisms in viral glycoproteins, most of 
which are hypervariable, may give rise to various epitopes, each possessing altering 
specificities for neutralisation from existing humoral responses
77–82
. Yet, further to this, recent 
studies have revealed that HCMV exhibits significant levels of genetic diversity within a 
single individual (i.e. at the intrahost level), demonstrating that HCMV evolution manifests on 
a short time scale, in the order of days or months
83,84
. Indeed, it is clear that mixed HCMV 
infections, which feature multiple genotypes within individual hosts, is common phenomenon 
affecting up to one half of all HCMV infections in a wide range of human populations, such 




. A number of plausible mechanisms underlying this mode of evolution haven 
suggested, each of which demonstrate clear potential to promote HCMV spatiotemporal 
evolution, and include: low frequency generation of de novo mutations, reinfection, genetic 
recombination and natural selection. Although no clear conclusion on the possible impact of 
any particular single genotype on disease has yet been reached, it is becoming increasingly 
understood that mixed genotype infections do in fact correlate with increased viral loads, 




For most healthy individuals, primary infection with HCMV generally manifests as a period of 
productive infection that is quickly limited by the host immune response, leaving behind a 
pool of latently infected cells that contribute towards lifelong persistence. Since it is not 
uncommon to observe the involvement of a range of organ systems in cases of overt 
pathology, this suggests that the virus is able to undergo efficient dissemination in vivo
65
. 
Indeed, the extent to which viral host spread can be attributed to cell-associated transmission 
between infected cells and uninfected tissues is supported by findings that very little 
extracellular virus is detectable in the plasma of HCMV-infected individuals, and furthermore, 
depletion of the peripheral blood compartment prevents lateral transmission of the virus
88–90
. 
Models describing HCMV pathogenesis during primary infection, but also reinfection, are 
therefore consistent in highlighting the importance of several host cell types that are likely to 
be involved in mediating the systemic spread of the virus
91
. For instance, epithelial cells lining 
the nasopharynx and urogenital tract, along with endothelial cells of the vascular tree, are 
regarded as major sites of HCMV acquisition, whose excretions also have the potential to 
transmit virus onwards through known oral, sexual and blood-borne routes
92,93
. By contrast, 
circulating blood leukocytes are believed to play an essential role in seeding the virus 
haematogenously, bringing into reach of infection the parenchyma of various organs such as 
the brain, retina, lung, liver and gastrointestinal tract, which have all been shown to manifest 
HCMV-associated disease
94
. Indeed, an HCMV cell-associated viraemia occurs early upon 
infection, with viral DNA being found predominantly in peripheral blood monocytes and 
polymorphonuclear leukocytes (PMNs) but not lymphocytes
95–97
. Though neither monocytes 
nor PMNs are able to support productive HCMV replication, they are still able to participate 
in the uptake and transport of infectious viral particles, which can then be transmitted focally 
through cell-associated contact
98–100
. Monocytes, in particular, have been characterised as 
highly motile carriers that feature as the most dominant infiltrating cell type seen in      
HCMV-infected tissues and are otherwise regarded as the principle cell type responsible for 
distributing the virus within the host
101
. Additionally, as a member of the myeloid lineage, 




. Thus, by acting as lifelong sources of periodic viral shedding, these 
particular infections underlie the pathological basis for causing recurrent disease. 
 
1.3. VIRAL-HOST CELL TROPISM 
 
HCMV possesses a broad cellular host range that is clearly notable from a clinical perspective. 
How the virus achieves such promiscuous cell tropism forms the basis of much ongoing study, 
which has contributed towards a better understanding of its basic pathogenicity. 
 
To begin with, all enveloped viruses gain entry into host cells by releasing their nucleocapsids 
into the cytosol
104
. This requires direct fusion between the virion envelope and cellular 
membranes, which may either occur at the level of the plasma membrane or endocytotic 
vesicle. Glycoproteins found in the virion envelope are responsible for mediating the viral cell 
entry process by binding to cognate cellular entry receptors, thereby triggering a sequential 
activation cascade that results in membrane fusion. For all herpesviruses, the ‘core’ fusion 
machinery comprises the heterodimeric glycoprotein complex gH/gL and the class III fusogen 
gB. According to the working hypothesis, multiple gH/gL complexes may exist to regulate the 
fusogenic activity of gB
105,106
. Thus, in the case of HCMV, two alternative forms of the 
gH/gL complex have been described and are regarded as important determinants of virus host 
cell tropism
107,108
. The first of the two complexes, gH/gL/gO, is a heterotrimer formed by 
gH/gL and a heavily glycosylated protein (gO; encoded by UL74), while the second,       
gH/gL/UL128-131, is a pentamer formed between gH/gL and three small glycoproteins 




Much prior research on the roles of each HCMV gH/gL-containing complex have been crucial 
in establishing the concept of a functional dichotomy for HCMV cell tropism. On the one 
hand,  viral entry into fibroblasts (the accepted standard cell type for HCMV tissue culture) 
depends on the presence of the gH/gL/gO trimer, which facilitates direct fusion at the plasma 
membrane
112
.  On the other hand, entry into more clinically relevant cell types such as 
epithelial cells, endothelial cells and myeloid cells, requires the gH/gL/UL128-131 pentamer, 
which instead, promotes the internalisation of HCMV through endocytotic pathways, thereby 
necessitating direct fusion at the vesicular membrane
113–116
. This dichotomy is broadly 
challenged, however, by the observation that gO-null mutants show a massive loss of cell-free 
infectivity with respect to all of the above cell types
117
. Hence, while both complexes are 
likely to be involved in conferring – or broadening, in the case of gH/gL/UL128-131 – the 
14 
relevant host cell tropism through their own respective receptor binding interactions, it is now 
understood that only the trimer preserves the core gH/gL function (i.e. activating gB-mediated 
fusion), which is strictly required for entry into all target cell types
118
. Interestingly,            
cell-associated spread in vitro is not compromised when gH/gL/gO is lacking. Rather, the 
removal of gO from a virus background impairs the release of infectious virions from infected 
cells, which causes viral spread to become focal and instead dependent on the pentameric 
complex
117,119
. This is reminiscent of recent work performed in vivo using murine 
cytomegalovirus (MCMV), demonstrating that while gH/gL/gO is important for the initial 
infection of mice, it is dispensable for subsequent viral spread to distal tissues and organs
120
. 
Recently, the cellular receptor for gH/gL/gO was identified as platelet-derived growth factor 
receptor alpha (PDGFR-α), which is expressed on fibroblasts, but not epithelial cells
121
. 
Although the identity of an equivalent receptor for gH/gL/UL128-131 remains unknown, 
there is evidence supporting the role of the pentamer in activating specific receptor-mediated 





Because the HCMV UL128-131 locus (encoding the pentamer-specific glycoproteins) is 
known to be genetically unstable during viral passage in fibroblast tissue culture, it is not 
surprising that the dichotomy concerning HCMV host cell tropism also exists on a broad scale, 
outside that of its own mechanistic underpinnings
26
. As such, frequently passaged    
laboratory-adapted strains of HCMV differ significantly from unpassaged clinical isolates, 
with the former having a restricted host cell range (i.e. poorly infecting endothelial, epithelial 
and myeloid cells, but not fibroblasts), while the latter retaining the ability to competently 
infect a broad range of cell types; a phenomenon that has previously been regarded as a 
surrogate marker of viral pathogenicity or attenuation in vivo
124–127
. Accordingly, numerous 
inactivating mutations have been detected within the UL128, UL130 and UL131 ORFs of 
laboratory-adapted strains, such as Towne and AD169, which correlate with an inability to 
form a functional gH/gL/UL128-131 complex, whereas gH/gL/gO remains unaffected
21,22
. 
Moreover, the prototype low-passage strain Merlin has been found to sustain a truncation of 
UL128 after only being passaged three times in fibroblasts, which is also associated with 
reduced incorporation of the pentamer in the virion and a loss of infectivity in epithelial 
cells
128
. It is therefore clear that any attempt to develop low-passage clinical isolates for the 
purposes of generating a laboratory strain of ‘wild type’ HCMV – which should otherwise be 
in possession of a naturally-occurring phenotype (let alone genetic sequence) – is significantly 
hampered by the rapid occurrence of genetic adaptation to cell culture
129
. Nevertheless, most 
15 
laboratory-adapted strains of the virus were historically developed by the process of serial 
passage in fibroblasts in an attempt to generate potential attenuated vaccine candidates. As 
such, the finding that sequential mutations associated with prolonged adaptation to fibroblasts 
is linked to greater resulting yields of cell-free virus, which can be used exogenously for in 
vitro experimentation, is crucial for supporting their continued application
130
. 
Moreover, it is now clear that both endothelial cell tropism and leukotropism can be reinstated 
in laboratory-adapted strains Towne and AD169 after they have undergone adaptation to 
growth in endothelial cell culture
131–133
. Hence, effective experimental design should 
necessarily take into account the choice of tissue type when wishing to generate experimental 
stocks of virus. Surprisingly, it has been reported that progeny virions produced by infected 
fibroblasts display a broader host cell tropism than those shed from infected endothelial cells, 
and that this relates to the cell type-dependent release of heterogeneous viral subpopulations 
that vary in terms of overall abundance of the pentamer
134
. While these findings are likely to 
have important clinical relevance with respect to understanding how instances of tropism 
switching may impact upon subsequent viral dissemination in vivo, they do not detract from 
the fact that repeated passage of broadly tropic HCMV strains can lead to loss of     
gH/gL/128-131 and a more stringent host cell range
135
. To this end, it is worthwhile restating 
that though clear interstrain differences in HCMV cellular tropism occur as an artefact of 
extensive cell culture, even heavily laboratory-adapted strains like AD169 are not rendered 




1.3.1. Lytic Replication and Control of the Major Immediate Early 
Promoter 
 
During HCMV infection, the virus may undergo one of two distinct transcriptional programs, 
resulting in either latency or lytic replication. As previously stated, latency represents a 
generally immunologically silent mode of persistence, which is broadly asymptomatic. In 
contrast, lytic replication underscores the production of new viral progeny, which leads to 
lysis of the host cell. While both states of infection are critical in mediating viral pathogenesis 
and spread, it is abundantly clear that clinically associated disease stems from a productive 
state of infection
137
. Accordingly, since this process proceeds in a highly coordinated, albeit 
cascade-like manner, involving the sequential activation of three temporal classes of lytic viral 




To begin with, levels of permissiveness for productive HCMV infection are highly dependent 
on the target cell type, as in particular, certain cells are known to maintain the virus in an 
otherwise latent state. However, it is well established that commitment to lytic replication is 
predicated on the ability to support IE gene expression, not least because IE gene products, 
most notably the nuclear phosphoproteins IE1-72 kDa (IE1; UL123) and IE2-86 KDa (IE2; 
UL122), are essential for mediating the subsequent expression of E and L lytic genes, which 




Broadly, the HCMV IE1 and IE2 proteins function as major viral regulatory factors, which 
are critical not just in controlling lytic infection, but also in priming the cellular milieu for 
virus production
139
. In detail, the IE1 protein synergises with IE2 to promote the 
transcriptional activation of early viral genes, though it is largely dispensable for HCMV 
replication at high multiplicities of infection (MOI)
140,141
. Contrastingly, the IE2 protein 
functions as a master regulator of HCMV transcription, one that is absolutely essential for 
facilitating progression down the lytic gene cascade
23,142
. The transactivation mediated by   
IE1 and IE2 appears to involve discrete and overlapping interactions with the basal cellular 
transcriptional machinery (including host chromatin remodelers), which have been shown to 
correlate with increased levels of activity from early viral promoters
29,143–146
. Beyond this, 
both viral factors have been implicated in modulating the host cell cycle during HCMV 
infection
147
. Only terminally differentiated cells in the G0/G1 phase of the cell cycle are fully 
permissive for lytic replication, as cells infected during the latter G2 or S phases fail to express 
IE genes, resulting in the development of abortive infections
148
. IE2, in particular, is believed 
to promote cell cycle progression from G0/G1 to G1/S, whereupon it arrests the cell cycle at 
the G1/S interface, thus allowing the virus to increase the vital pool of dideoxynucleoside 
triphosphates and biosynthetic enzymes required for DNA replication, while also subverting it 
(from the cell) for its own use
149
. Direct expression of IE2 has been shown to strongly activate 
an array of E2F-responsive genes that are principally involved in regulating DNA precursor 
synthesis and control of the cell cycle
150
. This activation is believed to be facilitated by the 
binding of IE2 to the tumour suppressor protein Rb of the retinoblastoma (RB) family of 
pocket proteins, which inactivates it, thereby relieving the repression of genes sensitive to 
E2F activity
151,152
. In turn, to promote cell cycle arrest at the G1/S checkpoint, HCMV 
engages in the stabilisation of another well-known tumour suppressor: p53
153
. Here, IE2 may 
target the p53-specific E3 ubiquitin ligase mdmd2 for degradation, which stops it from 
forming an auto-regulatory feedback loop with p53
154,155
. Additionally, IE1 and IE2 




.  To that end, IE1 can antagonise the type I interferon (IFN) response by forming 
complexes with human signal transducer and activator of transcription (STAT) proteins, such 
as STAT2, that are involved in the Janus kinase (Jak)-STAT signalling pathway, and 
redirecting them to nuclear chromatin compartments
157,158
. Whereas IE2 can target 
intranuclear NF-κB and prevent it from mediating the expression of inflammatory cytokines, 





Expression of IE1 and IE2, along with a vast majority of other IE gene transcripts, originates 
from a region located in the UL portion of the viral genome, termed the major IE (MIE) locus. 
This locus gives rise to a common primary transcript, composed of five exons, that undergoes 
alternative splicing to generate a number of distinct mRNA species (Figure 1.4). Among 
these, IE1 and IE2 are its most abundantly expressed products; both sharing 85 N-terminal 
amino acids corresponding to MIE exons 2 and 3, but containing distinct C-termini encoded 
by exon 4 in IE1 or exon 5 in IE2. For reasons not fully understood, this pattern of IE gene 
splicing is conserved among cytomegalovirus species even in the noted absence of amino acid 
homology
162
. The expression of the MIE precursor RNA is controlled by an upstream 
regulatory element located within the MIE locus, known as the MIE promoter/enhancer 
(MIEP). The MIEP is a highly potent and complex domain that is able to function in a        
tissue- and cell-type specific manner
163
. Hence, it contains binding sites for a diverse range of 
signal-regulated stimulatory and inhibitory eukaryotic transcription factors, whereby the        
cell-type specific promoter/enhancer activity is linked to the availability of appropriate factors 



















































 Figure 1.4 - Overview of transcripts originating from the MIE gene locus 
Figure 4. The MIE gene locus generates a single primary transcript that undergoes differential 
splicing and polyadenylation to produce multiple mRNA species. The IE1 and IE2 mRNAs, 
which respectively code for IE72 and IE86, are the most abundantly expressed transcripts. They 
share the first three exons, with IE1 containing exon 4 and IE2 containing exon 5. Minor 
isoforms are also produced from the IE1 and IE2 genes as illustrated; however, less is known 
about their functions due their relative low abundance, which makes them difficult to study 
independently. ENH: enhancer; TA: TATA box; CRS: cis repression sequence; INR: initiator; 
MIE: major immediate early; ATG: start codon; TAA: stop codon; AATAAA: polyadenylation 
signal; kb: kilobases; kDa: kilodaltons. Reproduced from Stinski and Petrik (2008) with 





















Over the last several years, it has become increasingly clear that the chromatin landscape 
surrounding the MIEP plays a fundamental role in determining the transcriptional output of          
IE genes following signal transduction
165
. This is explained by the fact that regulators of the 
MIEP facilitate transcriptional activation / repression by recruiting co-factors involved in the              
post-translational modification of histone proteins, an epigenetic component integral to the 
higher-order molecular structure inherent to both host genomes and viral episomes
33,166
.                
As a result, it has been shown that as virally infected cells acquire a more permissive 
phenotype (e.g. during reactivation from latency), corresponding changes in histone 
modification patterns are observed at the MIEP, suggesting the adoption of a more “open” 
chromatin conformation that favours the activation of lytic MIE genes
167
. Moreover, when 
human fibroblasts are pre-emptively treated with histone deacetylase inhibitors, such as 
trichostatin A (TSA), this appears to counteract the effects of negative regulators of viral 
transcription, resulting in a loss of repressive histone marks that correlate with increased levels 
of IE gene expression
168,169
. Yet, though these findings are important in establishing the 
relationship between chromatin structure and regulation of viral transcriptional activity, it 
remains noteworthy that evidence of    chromatin-mediated control – particularly at an early 
Figure 5. The HCMV MIEP comprises four distinct regions: a core promoter, an enhancer, a 
unique and a modulator region. Within the enhancer, a number of binding sites for known cellular 
transcription factors have been identified, enabling the region to be modulated by host 
mechanisms of gene regulation. NF-κB, CREB/ATF and YY1/ERF bind to the 18 bp, 19 bp and 
21 bp repeats, respectively. The transcription start site is designated by the forward arrow at + 1. 
Negative regulatory factors are highlighted by the blue shaded background. Reproduced with 
permission from Sinclair and Sissons (1996).  
 
Figure 1.5 – Structure of the HCMV MIEP 
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stage of infection – points to the likely involvement of intrinsic antiviral immunity, in which 
the negative regulation of viral IE genes offers the potential to restrict productive 
replication
170
. Thus, given that the MIEP appears to be targeted for initial repression upon 
infection, this raises the question as to how the virus may seek to counteract such an early 
response in order to enable lytic replication to occur. 
 
To account for the broad mechanism of intrinsic antiviral immunity, it is first necessary to 
consider the impact of nuclear events that place during the ‘pre-IE’ phase of HCMV infection 
(i.e. prior to the de novo expression of viral gene products, but immediately following cell 
entry). Although this broadly entails the rapid chromatinisation and circularisation of 
incoming viral DNA, of considerable importance is the fact that a vast majority of viral 
episomes come to form a close association with distinct nuclear complexes, previously 
referred to as ND10
171
.     These are highly dynamic clusters of protein found throughout the 
host cell nucleus, which are generally defined by the presence of core constituents PML, 
hDaxx and Sp100, but have also been known to contain up to 70 other different proteins 
(Figure 1.6)
172
. A vast majority of ND10 components are post-translationally modified by 
conjugation to small ubiquitin-like modifier (SUMO) moieties and it is widely understood that 
the functionality of ND10 are highly dependent on nature of these modifications
173
. In 
uninfected cells, for instance, SUMOylated forms of PML serve as the main scaffold protein 
for ND10, particularly as these are intimately involved in the assembly and maintenance of 
these structures as well as the recruitment of other ND10-associated proteins, such as 
hDaxx
174–176
. Though ND10 have been implicated in a number of cellular processes, including 
apoptosis, tumour suppression as well as senescence, they share a complex relationship with 
various DNA viruses (including herpesviruses, adenoviruses, and papovaviruses)
177,178
. With 
respect to HCMV, it was initially hypothesised that these structures were essential for viral 
replication since initiation of transcription was only found to occur at sites where viral DNA 
had become deposited to ND10
179,180
. However, there is now strong evidence that ND10 
manifest themselves as part of an innate defence against HCMV, along with other 
herpesviruses, specifically, by working against the onset of IE gene expression
181
. As such, 
treatment of cells with interferon enhances the expression of major ND10 constituents, such as 
PML or Sp100, resulting in an increase in both the number and size of ND10 structures
182
. 
Furthermore, depletion of each of the above core components has been shown to augment 
levels of MIE gene transcription following infection with HCMV, which goes on to support 
their individual identities as host restriction factors
183–186
. Of these, hDaxx remains one of the 
most studied in the context of lytic infection, and it has been shown that overexpression of this 
21 
factor in normally permissive cells renders them refractory to HCMV infection, whereas 
downregulation of hDaxx increases IE gene expression and subsequent virus 
propagation
187,188
. In addition, knockdown of hDaxx has been correlated with changes in 
chromatin structure at the MIEP, arguing for the ability of ND10 to impart its repressive 
effects through epigenetic modifications
185
. This finding appears to be linked to the ability of 
hDaxx to recruit ATRX, a known chromatin remodeler, where both form a complex that 
becomes sequestered to ND10
186,189
. Yet, it remains unclear as to whether PML or Sp100 may 
exert similar regulatory effects despite reports that these factors are also able to interact with 
other chromatin-modifying enzymes, such as histone deacetylases (HDACs) and 




























Figure 6. A. ND10 structures exist as discrete nuclear foci in most mammalian cells. They range 
from 0.2–1.0 μm in diameter and number between 1-30 bodies per nucleus, depending on the cell 
type, cell-cycle phase and stage of differentiation. ND10 are structurally and functionally 
heterogeneous, despite their uniform appearance. PML protein is necessary for the formation of 
ND10 and is heavily post-translationally modified. SUMOylation of PML is essential for ND10 
integrity and enables PML to interact with several other ND10 constituents, namely Sp100 and 
hDaxx, which recruits ATRX. Combined, these factors contribute to the intrinsic antiviral function 
of ND10. B. ND10 accumulations in uninfected human fibroblasts; cells stained for PML (red) 
and nuclei (blue) 
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From the virus’ perspective, a corollary to the presence of intrinsic defence mechanisms is the 
evolution of effective viral-based countermeasures. Naturally, therefore, most, if not all, 
herpesviruses possess the ability to overcome the antiviral restriction mediated by ND10 and 
encode a number of functionally diverse regulatory proteins to fulfil this role
178
. For herpes 
simplex virus type 1 (HSV-1), one of its IE gene products, ICP0, counteracts the effect of the 
repressive hDaxx /ATRX complex by inhibiting the SUMO interaction motif (SIM)-
dependent recruitment of hDaxx to PML, and thence to the parental viral genome itself
193,194
. 
Furthermore, ICP0 also exhibits an E3 ubiquitin ligase activity that allows it to induce the 
proteasome-dependent degradation of SUMOylated PML, which is required for ND10 
formation and consequent inhibitory effects on the virus
195,196
. In the case of HCMV, a closely 
related outcome of ND10 disruption is achieved by a different set of mechanisms involving 
two separate proteins. At the earliest stage of lytic infection, the tegument-derived pp71 
protein is responsible for alleviating the effects of hDaxx/ATRX-mediated repression, which 
as noted above, is responsible for silencing the MIEP. Briefly, upon its successful 
translocation to the nucleus, pp71 is posited to displace ATRX from ND10 as well as target 
hDaxx for degradation through a proteasome-dependent, but ubiquitin-independent 
pathway
186,197
. Given that pp71-mediated disruption of hDaxx/ATRX remains critical for 
robust MIEP activation and IE gene expression at the onset of lytic infection, it is thus of 
additional note that the HCMV IE1 protein itself also participates in neutralising the repressive 
effects of ND10. By contrast to pp71, however, IE1 is able to induce the dispersal of entire 
ND10 structures, resulting in the complete displacement of ND10-associated proteins
198
 . To 
account for this, studies have shown that IE1 promotes the loss of SUMOylated PML, akin to 
the function of HSV-1 ICP0
199
. Similarly, IE1 has also been shown to promote the loss of 
SUMOylated Sp100 proteins
184
. Though, interestingly, IE1 does not appear to possess any 
intrinsic ubiquitin ligase or SUMO protease (deSUMOylase) activity, giving rise to the notion 
that it may perhaps function by recruiting other cellular factors to remove SUMO from PML 
or Sp100 by preventing each of their respective isomerisation through an as yet undefined 
mechanism
200,201
. Importantly, consistent with the roles of pp71 and IE1 in separately 
counteracting the antiviral effects of hDaxx/ATRX and PML, respectively, HCMV 
inefficiently enters productive infection in the absence of pp71 or IE1 unless hDaxx/ATRX or 
PML are depleted prior to infection
187,202,203
. Furthermore, the finding that knockdown of 
hDaxx in combination with PML leads to a further increase in the efficiency of wild type 
HCMV replication, also provides additional evidence for the independent involvement of each 
of these factors in restricting HCMV
204
. Moreover, since Sp100 has been characterised as one 
of the first ND10-related factors to exhibit the potential to inhibit HCMV replication at a late 
23 
stage of infection, it is noteworthy that IE1 may also help to induce the proteasome-dependent 
degradation of unSUMOylated Sp100 during this period; however, the exact mechanism by 




Taken together, this information may be used to create a working model that describes the 
crucial early events which occur during a typical HCMV infection in permissive cell types:              
(i) immediately following cell entry, parental viral genomes become targeted by ND10 in           
the nucleus, resulting in the formation of repressive chromatin around the viral DNA;                
(ii)  once viral tegument-delivered pp71 is imported into the nucleus, it antagonises 
hDaxx/ATRX-related repression, which then permits the initiation of viral IE gene expression; 
(iii) the expression and accumulation of high levels of IE1 helps to subsequently overcome 
PML-mediated suppression, which in turn induces the dispersal of ND10; (iv) the combined 
modification of ND10 relieves the broad effects of transcriptional repression on viral genomes 
deposited in the nucleus, which subsequently correlates with efficient lytic infection          

















































Figure 1.7 – Interplay of HCMV and ND10 components during lytic infection  
In cells permissive for 
productive HCMV infection, 
viral pp71 protein is capable 
of entering the host nucleus 
in order to target hDaxx for 
degradation. 
 
pp71-induced reduction of 
hDaxx relieves repression of 
the viral chromatin, which 
leads to initiation of viral IE 
gene expression and 
production of the key lytic 
viral transactivator IE1. 
 
IE1 localises to ND10 to 
promote the complete 
disruption of this structure. 
ND10 dispersal by IE1 
correlates with efficient 
lytic viral replication. 
Reproduced from Tavalai 
and Stamminger (2008) 






1.4. HCMV: LATENCY 
 
Strategies that limit the possibility of eradication following primary infection are collectively 
employed by herpesviruses to promote lifelong persistence within the infected host. Most 
notable among these is the hallmark ability of herpesviruses to enter a latent state of infection, 
insofar as adopting a quiescent phenotype. Not only does this benefit the virus from avoiding 
clearance by the host immune system, it nonetheless leads to the establishment of latent viral 
reservoir that has the recognised potential to spread and recrudesce over time. 
 
Viral latency, by way of preamble, may be operationally defined as the retention of virus 
genome in the absence of infectious virion production – which, upon appropriate stimulation, 
can be reversed to promote reactivation followed by lytic replication
205
. While this definition 
does not preclude the possibility of an array of viral gene transcripts from becoming expressed 
during the latent period, it nonetheless distinguishes latency from an otherwise persistent viral 
infection involving low levels of ongoing productive replication (cf. patients with chronic 
Hepatitis C).  
 
During latent infection, herpesviruses exhibit a number of common phenotypic features. The 
relative lack of lytic viral gene expression is by far the most crucial, but other aspects of note 
include the maintenance of virus genome in the form of nuclear episomes (with the notable 
exception of HHV-6) and the restriction of latency to specific cellular sites in the body. 
Knowledge of these distinct properties grant insight into the essential processes that govern 
herpesvirus latency, which are complex, but very closely interlinked, and above all, 
responsible for conferring control over virus gene expression.   
 
1.4.1. Current Model of HCMV Latency in the Context of Natural 
Infection 
 
Prior to the advent of PCR-based technology, attempts to define the location(s) of latent 
carriage of HCMV were hindered by an inability to detect viral genomes in seropositive 
individuals. Nonetheless, that at least one major site of latency was likely to be found in the 
peripheral blood compartment came from early clinical observations in which             
leukocyte-depleted blood products could significantly reduce the rate of HCMV transmission 
from asymptomatic carriers
206–208
. Current evidence now supports this view, in that, 
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specifically, cells of the early myeloid lineage represent sites of natural latency in vivo
209
. 
Through the use of more sensitive assays, the presence of latent viral genomes have been 
detected in peripheral blood monocytes and granulocyte-macrophage precursors as well as 
CD34
+
 haematopoietic stem cells resident in the bone marrow
95,210,211
. These results have 
since been recapitulated under in vitro conditions, supporting the general view that myeloid 
progenitor cells, including their monocytic derivatives, are not susceptible to productive 
HCMV infection and are able to maintain viral genomes in the absence of lytic gene 
expression
103,212,213
. Interestingly, members of the lymphoid lineage of haematopoiesis 
(i.e. peripheral blood B or T cells) do not appear to harbour latent viral genomes, despite them 




. How such lineage specificity may be exhibited 
on the part of latent carriage remains unclear, but one suggestion is that latent infection itself 
may help to promote commitment to the myeloid lineage
215
. Nonetheless, these results do not 




As lineage commitment progresses, however, myeloid cells cease being able to maintain 
HCMV in a latent state, and instead, become associated with viral reactivation from latency. 
The differentiation of myeloid progenitors to macrophage-like cells or dendritic cells has been 
shown to trigger reactivation in natural and experimental systems of HCMV latency, leading 
to the expression of all classes of lytic viral genes and the production of infectious 
virions
219,220
. Such a phenomenon is consistent with the finding that terminally differentiated 
myeloid cells are fully permissive for productive HCMV infection, like that of infected 
fibroblasts
221,222
. These results thus lend credence to the notion that myeloid cells act 
conjointly as sites of HCMV latency as well as reactivation in vivo, with the state of cellular 
differentiation serving as the crucial link between the two events
209
 (Figure 1.8). In line with 
this, recent analysis of clinical samples taken directly from HCMV-seropositive individuals 
has revealed that late-differentiated myeloid cell types (i.e. circulating dendritic cells and 
alveolar macrophages) undergo clear lytic gene expression and are capable of supporting viral 




Because latent viral genomes are carried by a very small population of naturally infected cells 
(approximately 0.004–0.01% of monocytes, at around 2–13 genome copies per cell), it is not 
surprising that several model systems of HCMV latency have been developed to complement 
the study of its related mechanisms
224
. For instance, models of experimental latency, which 
make use of precursor cell lines (e.g. myelomonocytic THP-1 and teratocarcinoma NT2D1 
cell lines), are known for their intrinsic ability to block the expression of viral lytic genes and 
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thereby support latency, except upon differentiation
225,226
. These in vitro systems have been 
instrumental in identifying the cellular factors that modulate latent HCMV infection, even 
though they only provide a snapshot of the virus life cycle as they are unable to fully 
reactivate latent viral genomes and participate in new virion production
227–234
. By contrast, ex 
vivo models of latency, which are based on the infection of primary myeloid cells, provide an 
arguably more complete view of HCMV latency, given that these are able to recapitulate the 
production of infectious virus as the defining characteristic of viral reactivation
235–237
. Though, 
in utilising these more robust systems, one must take into account the limitations of primary 
cell culture, notably isolation costs, coupled with finite numbers of cells, reduced life spans ex 
vivo, and implicit donor variation. These negative aspects make them impractical for certain 
methodological applications, such as the generation of stable cell lines with which to employ 
molecular biology techniques for manipulating gene expression. Yet, as there has not been a 
suitable animal model for HCMV, clinical evidence remains critical for arriving at conclusions 
that are material to the in vivo situation; however, in vitro analysis still has the potential to 
offer important insight
238
. Indeed, experimental research into the mechanisms regulating 
HCMV latency has led to the discovery of novel extracellular stimuli that can promote viral 
reactivation following treatment, either, by triggering cellular differentiation (akin to 
conventional cytokine stimulation) in the case of vitamin D3 or by directly activating lytic 
gene expression as with dexamethasone
239,240
. These reagents can be used as tools to promote 
the study of HCMV in model systems without necessarily compromising their capacity to 





























Following primary HCMV infection, the virus establishes a lifelong latent infection in CD34
+
 stem cells residing in the bone marrow as well as 
circulating CD14
+
 monocytes. Viral latency is characterised by the maintenance of virus genome in the concomitant absence of infectious 
virion production. During this period, a number of HCMV latency-associated genes become expressed (green arrows), but there is restricted 
expression of lytic viral genes. This is underscored by chromatin-mediated repression of the viral MIE genes (yellow arrow with black cross), 
which otherwise serve as the main viral transactivators. Once these immature cell types have undergone terminal differentiation, however, to 
become either mature dendritic cells or macrophages, the latent viruses become triggered to reactivate, resulting in the detectable expression of 
MIE genes, along with all other lytic temporal classes (red arrows) and the subsequent production of new infectious virions. 
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1.4.1. Regulation of HCMV Latency 
 
One of the most crucial elements in regards to HCMV latency concerns the specific control of 
viral IE gene expression, particularly as the induction of these genes is inseparable from the 
otherwise divergent lytic temporal cascade. As such, the MIEP (which is responsible for 
directing the expression of major viral transactivators IE1 and IE2) appears to be subjected to 
a differentiation-dependent transcriptional regulation, thereby reflecting the relationship 
between the differentiation status of the host cell and the permissiveness for HCMV to 
undergo productive replication
209
. Indeed, binding sites for multiple cellular transcription 
factors have been located within the MIEP, and it has been posited that the relative balance of 
these factors in a given cell type serves as an upstream determinant of HCMV IE gene 
expression
163
. During latency, it is likely that this balance favours interactions with known   
co-repressor complexes, made of up host chromatin remodelers which help to catalyse the 
local formation of repressive histone modifications and aid in nucleosome compaction
165
. So 
far, the nuclear transcription factors Yin Yang 1 (YY1), Ets-2 repressor factor (ERF), growth 
factor independent 1, and more recently, KRAB-associated protein 1 (KAP1) have all been 
shown to act as negative regulators of the MIEP in non-permissive cells, where they facilitate 
the local recruitment of HDACs and HMTs that go on to repress its activity
241–244
. As referred 
to earlier, nucleosome occupancy in tandem with post-translational histone modifications 
have been intimately linked to the timing and extent of transcription from the MIEP, revealing 
themselves to be critical in influencing the outcome of not just lytic, but also latent infections. 
Accordingly, under latent conditions, the MIEP has been found to be maintained in a 
repressed chromatin state, as demonstrated by its association with reduced levels of histone 
H4 acetylation as well as increased levels of histone H3 trimethylation at lysine 9 (H3K9me3) 
and 27 (H3K9me27)
167,245
. The latter of these serve as targets for recruitment of HP-1 and 
Polycomb group proteins, respectively, which are well established to play key roles in 
augmenting transcriptional silencing
230,246
. Importantly, the detection of IE gene transcription 
is consistent with these histone modification patterns, with in vitro models of latency 
exhibiting weak and transient expression of IE1, accompanied by undetectable levels of IE2, 
while in a similar manner, latent infection of primary myeloid cells displaying the sporadic 
expression of both genes
247,248
. Notably, the recent observation that treatment of latently 
infected cells with histone deacetylase inhibitors results in a transient induction of IE gene 
expression is highly supportive of a role for chromatin structure in regulating the MIEP 
during latency
249
. It is only upon terminal cellular differentiation – which triggers viral 
reactivation – that a robust expression of IE genes is observed and the chromatin 
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configuration at the MIEP becomes subsequently altered, incurring changes such as a loss of 
HP-1 and an increase in levels of histone acetylation
167
.  
Despite the fact that regulation of viral IE gene expression remains critical for HCMV latency, 
there is now strong evidence demonstrating that latent infection requires more than just 
silencing of lytic gene expression and that efficient latent carriage is associated with the ability 
of HCMV to efficiently undergo viral gene expression
247
. Indeed, clear differences in the 
epigenetic landscape across the virus genome have been detected in latently infected cells, 
supporting the existence of viral gene transcription throughout this period
245
. Thus, during 
latent infection, it has been shown that HCMV incorporates a programme of gene 
transcription, one which does not fall into a regulated cascade as that of a lytic infection and is 
otherwise severely restricted in its overall degree of expression
250–252
. Yet, the general 
properties that characterise latency (i.e. low levels of viral genome carriage and corresponding 
gene expression) have made it difficult to understand molecularly. Until recently, the latent 
transcription programme was presumed to be limited to a discrete number of viral RNAs and 
proteins, as chiefly defined by compiled microarray data. However, global transcriptome 
analysis of HCMV latency – facilitated by the application of next-generation sequencing 
(NGS) techniques – indicates that the extent of viral gene expression during latent carriage 
may be far wider than first thought
245,253
. Additionally, when a single-cell approach is used, it 
appears that there may be stages of latency establishment which eventually result in a latent 
transcriptome with some qualitative changes (e.g. a lack of major IE gene expression) but 
mainly quantitative differences in viral gene expression, one that bears some form of 
resemblance to a lytic state of infection
254
. In spite of several caveats accompanying these 
interpretations, most notably the difficulties in safeguarding the potentiality of unbiased reads 
from lytic transcriptional noise, it is now clear that the notion of strict quiescence during viral 
latency is being challenged such that it may be far more complicated than previously 
appreciated
255
. Nevertheless, this has not diminished the importance of ongoing investigations 
towards the identification and functional characterisation of individual latently expressed 
transcripts, on grounds that they are likely to serve important roles in mediating latent HCMV 
infection
256
. Consequently, a number of distinct viral gene regions or ORFs have been defined 
as being transcriptionally active during latency, with the products of these ORFs being divided 
into two separate groups of either: cytomegalovirus latency-specific transcripts (CLTs), which 
denote spliced and unspliced RNAs sourced from both strands of the MIE region, or other so-
called LATs, which are encoded by the rest of the genome and found to be expressed during 
both latent and lytic phases of infection (albeit with their expression during lytic infection 
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being IE gene dependent)
209
. Below, Table 1.3 outlines the identities and known functions of a 
number of these latently expressed transcripts.  
 
Table 1.3 – Gene products and functions during latency and lytic infection [Adapted from: 
Sinclair and Reeves. Viruses (2013)] 





Regulation of antiviral 2’5’ 





Regulation of RNFRI and 
MRP1, repression of the MIEP 
Regulation of TNFRI and 











Down-regulation of MHC 
class II expression, immune 
evasion 
Unknown – cmvIL-10 is 





Binds Polycomb repressor 





UL84 Genome maintenance 






Attenuates MAPK and NF-κB 
signalling, maintenance of 
latency 
GPCR, induces cell signalling 





TNF superfamily member, 
hijacking of NF-κB signalling, 




Although the full extent of the latent transcriptome and its properties remain to be elucidated, 
it is nonetheless clear that the successful establishment and maintenance of HCMV latency is 
dependent on the expression of latent viral genes. This stems principally from the fact that 
manipulation of the cell by the virus is required to confer conditions necessary to support 
latency
284
. Here, the specific functions of a subset of LATs, namely UL138, UL144, viral 
interleukin-10 (latency-associated CMV homologue of IL-10 [LAcmvIL-10]) and IE1x4 will 
be discussed further.   
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To start with, UL138 was the first viral gene product to be characterised as an important 
determinant of latent infection. Recombinant viruses lacking UL138 were found to be unable 
to establish latency in primary myeloid cells, showing commensurate levels of productive 
replication
260
. One possible mechanism by which UL138 may promote latency is by 
maintaining the MIEP in a transcriptionally repressed state. This is backed up by recent 
evidence demonstrating that expression of UL138 inhibits the local recruitment of histone 
demethylases, thereby limiting the potential for the repressed chromatin signature found at the 
MIEP to become reversed
285
. Although the UL138 gene appears to encode a 21-kDa type-1 
transmembrane protein that localises to the Golgi apparatus, how it precisely functions 
remains unclear
260
. One hypothesis posits an involvement in the vesicular trafficking of host 
cell receptors, given that UL138 expression is associated with decreased surface levels of 
multidrug resistance-associated protein 1 (MRP1) – which incidentally improves the killing of 
latently infected cells by vincristine – but increased levels of tumour necrosis factor receptor 1 
(TNFR1) and epidermal growth factor receptor (EGFR). In the case of EGFR, activation of its 
associated downstream signalling pathways (i.e. PI3K and ERK/MAPK) has been shown to 
enhance survival of the latently infected cell by inhibiting caspase 3 activation. Consequently, 
it is also possible that signalling events stemming from such UL138-mediated regulation of 
EGFR or indeed other receptors might be responsible for precipitating changes in epigenetic 
silencing. Notably, because the UL138 gene is located in the ULb’ region of the virus genome, 
its expression is naturally inherent to low-passage clinical isolates. Yet, interestingly, studies 
performed using laboratory-adapted strains – which do not possess the ULb' region – have 
indicated that the ULb’ is not essential for latency establishment in vitro, calling into question 
the role of UL138 in the latently infected cell
259
. Since low-passage strains are considerably 
more robust than their laboratory-adapted counterparts in establishing latency, this has led to 
the general assumption that UL138, along with other ULb’ genes – known also to be latently 





Like UL138, the UL144 ORF is also located in the ULb' region of the genome. Though not 
required for latency establishment, it has however been implicated in promoting optimal 
latency, supporting the view that multiple UL/b′ genes contribute towards this process
259
. 
Specifically, UL144 encodes a transmembrane protein that is a structural homologue of the 
herpesvirus entry mediator HVEM
283
. Under normal conditions, HVEM functions as part of 
the signalling network HVEM-LIGHT-BTLA, which is broadly implicated in orchestrating 
inflammation and homeostasis of lymphoid microenvironments
287
. In this respect, UL144 
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engages with the HVEM ligand, BTLA, initiating an inhibitory signalling response that 
downregulates T cell proliferation
288
. Thus, it has been proposed that HCMV may use UL144 
to inhibit T cell immune responses in order to prevent clearance of the virus. Indeed, despite 
clinical isolates of HCMV exhibiting clear sequence variation in the ectodomain of UL144, all 
are known to retain selective binding to BTLA, but not other ligands, such as TNF-α and 
LIGHT (a known antagonist to BTLA)
289
. This argues for significant immunological pressure 
in shaping the evolution of this molecule. Additionally, the intracellular domain of UL144 is 
understood to signal via NF-κB, TRAF6 and TRIM23, which leads to the induction of the 
chemokine CCL22, a known TH2 chemoattractant that can help subvert the TH1 immune 
response
280,281,290
. Nonetheless, whether such signalling through this pathway is important for 
latency remains unclear.  
 
Homologues of the host immunomodulatory cytokine interleukin-10 (IL-10) are expressed by 
HCMV, comprising two major isoforms encoded within the UL111A gene region. During lytic 
infection, UL111A is expressed as a doubly spliced transcript, denoted as cmvIL-10
291
. 
However, under latent conditions, a latency-associated form of cmvIL-10, termed      
LAcmvIL-10, is also transcribed
267
. Despite their close sequence similarity, which includes 
shared usage of the same translation initiation site, both transcripts undergo differential 
splicing that results in    LAcmvIL-10 retaining one of two introns found in cmvIL-10
267
. In 
terms of function, like its nearest counterpart, LAcmvIL-10 demonstrates a clear ability to 
downmodulate the activities of  MHC class II presentation in early myeloid cells
292
. As such, 
expression of recombinant  LAcmvIL-10 has been associated with reduced delivery of MHC 
class II to the cell surface as well as reduced levels of transcription of MHC class II 
components, such as invariant chain
268
. Though, in contrast to cmvIL-10, LAcmvIL-10 is 
unable to exert an immunosuppressive effect on DC maturation, which is thought to be linked 
to the inability of LAcmvIL-10 to bind to the human IL-10 receptor
293
. Nevertheless, in the 
context of latent infection, LAcmvIL-10 has been shown to render cells refractory to CD4
+
 
cell recognition, thus implicating its role in helping to maintain latent viral carriage in 




IE exon 4 (IE1x4) is a recently identified LAT that is reported to be encoded by exon 4 of 
IE72. Despite its clear association with lytic gene expression, Tarrant-Elorza et al. observed 
that IE1x4 could be expressed in latently infected CD34
+
 cells as a discrete gene product
295
. 
The protein was shown to tether plasmids containing HCMV maintenance elements to cellular 
chromatin through interactions with host topoisomerase IIB and DNA binding protein Sp1, 
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revealing a possible mechanism for latent viral genome carriage to be maintained during cell 
division. This finding strengthens the argument for genome replication during latency, which 
while known to be generally inefficient and not consistently documented throughout the 




1.4.1. UL81-82 antisense transcript / LUNA 
 
The UL81-82 antisense transcript (UL81-82ast) is a latently expressed viral gene product 
encoded by the UL81-82 locus of the HCMV genome. It was originally discovered by                      
Bego et al., who observed that transcription of this mRNA originated from the opposite strand 
encoding the UL81 gene while being partially antisense to UL82
264
. The transcript give rises 
to a putative 133 amino acid serine-rich protein, termed LUNA (Latency Unique Nuclear 
Antigen), which appears to be highly conserved across both clinical- and laboratory-derived 
strains of HCMV as well as chimpanzee CMV. The protein has been transiently detected in 
human fibroblasts early upon lytic infection, but it is nonetheless considered to be         
latency-associated, owing to its stable expression under latent conditions in vitro
263
. As such, 
its presence has been confirmed in primary monocytes and CD34
+
 myeloid progenitor cells 
isolated from healthy HCMV-seropositive donors in the absence of lytic viral gene 
expression
265
. In certain cases, the detection of LUNA-specific antibodies in the sera of other 
such carriers provides strong evidence that LUNA is also able to be produced in vivo and has 




To date, only a few attempts have been made to characterise the role of the LUNA protein 
during HCMV latency. While no precise function has yet been attributed to it in natural 
latency, studies on experimental latency have nonetheless been informative, implicating the 
protein in latent carriage and viral reactivation. In a study devised by Keyes et al., the function 
of LUNA in HCMV latency was evaluated through the use of a LUNA deficient virus that had 
been generated by BAC mutagenesis in the FIX strain backbone
266
. The impact of this         
FIX-∆LUNA virus was explored in various models of infection that reflected settings of 
permissiveness for productive infection or latency establishment. Notably, FIX-∆LUNA was 
able to undergo productive infection in fibroblasts, indicating that LUNA was dispensable for 
lytic replication. However, latently infected CD14
+
 monocytes carrying FIX-∆LUNA failed to 
express detectable amounts of the UL138 latency-associated transcript, which given its 
requirement for latency establishment, suggested that LUNA was important in promoting 
35 
efficient UL138 expression in order to mediate this process. Moreover, FIX-∆LUNA virus 
failed to reactivate from infected CD14
+
 cells following differentiation. 
 
1.5. Aims and objectives 
 
The principal focus of this research is to improve our understanding of the general 
mechanisms that underlie HCMV latency. As outlined earlier, the expression of            
latency-associated viral gene products appears to be important for latent HCMV infections, 
warranting their use for further study. Thus, to achieve the stated objective, an investigation 
will be carried out to evaluate the functional significance of LUNA, an example of one such 
viral gene product known to be expressed during latency. 
 
To the extent that LUNA is implicated in regulating HCMV latency, its expression has 
already been associated with the efficient transcription of UL138, which may be important 
for the proper establishment of latent infection. Indeed, in this context, LUNA is also 
required for the reactivation of latently infected cells. Assuming that the augmentation of 
latency-associated virus gene expression is necessary for latent viral genomes to remain 
responsive to appropriate environmental cues, one may hypothesise that LUNA is 

















2.1.1. Solutions and buffers 
 
Complete media:  RPMI-20 
- RPMI-1640 (Sigma-Aldrich)  
- 20 % (v/v) Foetal Calf Serum (FCS) 
- 1 % Streptomycin (Pen/Strep) 
 DMEM-10  
- DMEM (Life Technologies Ltd.) 
- 10 % (v/v) FCS 
- Pen/Strep 
Haematopoietic Media  
- X-Vivo 15 with Gentamicin, L-glutamine and phenol 
red (Lonza) 
 
Freeze mix:   90 % FCS: 10 % dimethyl sulfoxide (DMSO) 
 
TE buffer:   10mM Tris pH 8.0 
    1mM EDTA 
 
Magnetic separation buffer: 1 × Phosphate Buffered Saline (PBS) (Lonza) 
    2 mM EDTA (Sigma-Aldrich) 
0.5 % (v/v) FCS 
    
2 × Laemmli sample buffer: 0.125 M Tris-HCL, pH 6.8 
    20 % (v/v) glycerol 
    4 % (v/v) SDS 
    1.25 % (v/v) 2-Mercaptoethanol 
    0.004 % (v/v) bromophenol blue 
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SDS-PAGE buffer:  3 g/L Tris-base 
    14.4 g/L glycine 
    1 g/L SDS 
    ddH2O to 1 litre 
         
Transfer buffer:  1 g/L Tris-base 
    4.8 g/L glycine 
    20 % (v/v) methanol 
    ddH2O to 1 litre 
 
12 % Resolving gel:  10 mL acrylamide  
    3.75 mL 0. 5M Tris, pH 8.8 
    0.3 mL 10 % SDS 
    16.95 mL dH2O 
    15 µL TEMED  
    1 mL 1.5 % ammonium persulphate 
 
12 % Stacking gel:  2.5 mL acrylamide  
    5 mL 0.5 M Tris, pH 6.8 
    0.2 mL 10 % SDS 
    11.3 mL dH2O 
    15 µL TEMED  
    1 mL 1.5 % ammonium persulphate 
 
ChIP cell lysis buffer:  50 mM Herpes pH 7.9 
     140 mM NaCl 
    1 mM EDTA pH 8.0 
    10 % (v/v) glycerol 
    0.5 % (v/v) NP-40 
    0.25 % (v/v) Triton X-100 
    1 × cOmplete™ EDTA-free protease inhibitor cocktail (Roche) 
 
ChIP wash buffer:  10 mM Tris-HCl pH 8.0 
     200 mM NaCl 
    1 mM EDTA pH 8.0 
    1× cOmplete™ EDTA-free protease inhibitor cocktail 
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Shearing buffer:  0.1 % w/v SDS 
     1 mM EDTA 
    10 mM Tris-HCl pH 8.0 
    1 × cOmplete™ EDTA-free protease inhibitor cocktail  
 
IP Dilution buffer:  20 mM Tris pH 8.1 
     2 mM EDTA 
    150 mM NaCl 
    1 % Triton X-100 
    0.01 % SDS 
1 × cOmplete™ EDTA-free protease inhibitor cocktail  
 
IP Wash buffer 1:  20 mM Tris pH 8.1 
     2 mM EDTA 
    50 mM NaCl 
    1 % Triton X-100 
    0.1 % SDS 
 
IP Wash buffer 2:  10 mM Tris pH 8.1 
     1 mM EDTA 
    0.25 M LiCl 
    1 % sodium deoxycholate monohydrate 
    1 % NP-40 
 
Elution buffer:  100 mM NaHCO3 
     1 % SDS 
 
RIPA lysis buffer:  50 mM Tris pH 7.4 
     1 % Nonidet P-40 (NP-40) 
    150 mM NaCl 
    0.25 % sodium deoxycholate monohydrate 
    1 % NP-40 






Reporter plasmids containing viral promoter regions driving luciferase expression were based 
on pGL3 (Promega). These included pGL3-UL144 and pGL3-LUNA, and were kind gifts of 
Emma Poole (Department of Medicine, University of Cambridge). LUNA gene expression 
vectors were based on pCMV-Tag2b (Stratagene). Plasmids encoding for FLAG-tagged WT 
LUNA (pCMV-Tag2b-FLAG-LUNA) and FLAG-tagged LUNAg233c point mutant (pCMV-
Tag2b-FLAG-g233c) were kindly provided by Emma Poole and Matthew Reeves (Institute of 
Immunity and Transplantation, University College London). To generate FLAG-tagged WT 
LUNA, the LUNA coding region was excised from a previously published PET102UL82as10 
LUNA expression (BamHI/HindIII) casette and inserted directly into pCMV-Tag2b in-frame 
with the FLAG-encoding sequence
263
. To generate the FLAG-tagged LUNA g233c point 
mutant, a guanine-to-cytosine transition was introduced by site-directed mutagenesis at position 
233 of the LUNA nucleotide sequence, substituting cysteine for an activate serine residue. 
Plasmid pEF-BOS-GATA-2 was a kind gift of B. Gottgens (Cambridge, United Kingdom).  
 
2.1.3. HCMV strains 
 
eGFP-expressing variants of low passage HCMV strain TB40E (BAC-derived viruses      
TB40-BAC4) were kindly gifted by Michael Nevels (University of St. Andrews, St. 
Andrews, United Kingdom). These included WT phenotypic revertant (rvIE1), IE1-deficient 
mutant (dlIE1) and IE1 exon 4 deletion mutant (dlIE1ex4) viruses. All were derived from a 
modified bacterial artificial chromosome (BAC) containing an SV40-eGFP-BGH PolyA 
cassette inserted between viral US34 and TRS1 genes. An IE2-RFP tagged HCMV        
TB40-BAC4 variant was a kind gift of Betty Lau (University of Cambridge, Cambridge, 
United Kingdom). 
 
BAC recombineering in the clinical reference strain Merlin (pAL1174) containing a     
UL32-GFP fusion reporter was performed to generate wild-type phenotype and mutant viral 
constructs. These included Merlin (WT), LUNA translation mutant (LUNA Del) and LUNA 
functional / catalytically inactive mutant (g233c). For LUNA Del, a cloning strategy was 
adopted to introduce a guanine to adenine exchange at nucleotide position 118965, mutating 
the tryptophan (TGG) to a stop codon (TGA). Because the codon change on the anti-parallel 
strand (ACC → ACA) was redundant for threonine, it was possible to maintain the integrity 
of corresponding pp71. Similarly, for g233c, to disrupt the predicted SUMOylation activity 
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without affecting pp71, a guanine to cytosine nucleotide exchange at position 233 of the 
LUNA nucleotide sequence resulted in the replacement of cysteine for a serine residue at 
nucleotide position 119197. Following sequence verification, the recombinant BAC viruses 
were transfected into fibroblasts using lipofectamine 2000 according to the manufacturer’s 
instructions in order to reconstitute infectious virus. A revertant virus (Rev) was constructed 
from the LUNA Del virus using the same cloning strategy, but an equivalent phenotype virus 
was not generated from g233c. As shown subsequently, the Rev virus was identical to the 
WT parental virus in growth kinetics in fibroblast cell systems and was used as the primary 
wildtype phenotype control virus in HCMV infection experiments.  
 
2.2. PRIMARY CELL CULTURE 
 
2.2.1. Ethics statement 
 
Ethical permission for this study was granted by the Cambridgeshire 2 Research Ethics 
Committee in accordance with the Declaration of Helsinki (REC reference 97/092). 
Informed written consent was obtained from all volunteers prior to providing blood samples.  
 
2.2.2. Human CD14+ mononuclear cell preparation  
 
Venous blood was obtained from healthy donors by venepuncture, performed by a qualified 
phlebotomist. To prevent clotting, blood was diluted 1:1 in PBS containing 10 U/mL heparin 
sodium salt (Wockhardt UK Ltd.). Ficoll-Hypaque density gradient centrifugation was 
performed by layering 25 mL blood solution on to 12.5 mL Lymphoprep (Axis-Shield) and 
spinning at 800 g for 15 mins with no brake. Peripheral blood mononuclear cells (PBMCs) 
were then extracted from the plasma-Ficoll interface using sterile Pasteur pipettes, before 
being washed twice and resuspended in sterile PBS (Sigma-Aldrich). Positive selection using 
antibody-conjugated MicroBeads (Miltenyi Biotec) allowed collection of a 
CD14
+
 mononuclear cell-enriched population. Briefly, PBMCs were resuspended in magnetic 
separation buffer and incubated with 20 µL anti-CD14-coated microbeads per 10
7
 cells for 20 
mins at 4°C, before being layered on a MACS
®
 LS column prewetted with 3ml magnetic 
separation buffer. Bound cells were then washed three times in 3mL magnetic separation 
buffer, before being eluted in 3ml PBS. The isolated mononuclear fraction was plated to a 
density of 2 × 10
6
 cells in 100mm dishes for ChIP assays, 5 × 10
5
 cells/well in 24-well plates 
for RT-qPCR analysis, or to 1 × 10
5
 cells/well in 96-well plates for immunofluorescent 
staining, and then incubated at 37°C, 5 % CO2 for 2-3 hours to promote adherence. The PBS 
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was removed and replaced with X-Vivo 15; 10 ml for 100 mm dishes, 1 ml per well for             
24-well plates or 200 µL per well for 96-well plates. 
 
2.2.3. Human CD34+ myeloid progenitor cell preparation  
 
Cryopreserved human bone marrow CD34
+
 progenitors isolated from granulocyte-colony 
stimulating factor (GCSF) mobilised healthy donors were purchased from Lonza and 
resuscitated according to Lonza’s ‘Procedure for thawing Poietics
™ 
cells’ with modifications. 
Ampoules were rapidly thawed by direct immersion in a 37°C water bath and diluted into a 
large volume of pre-warmed thawing media [X-Vivo 15, supplemented with 1 % BSA and 
DNase I (Sigma) at 20 U/ml], added in a drop-wise manner with gentle swirling. Solutions 
were pelleted by centrifugation at 200 g for 15 minutes, after which cells were resuspended 
in 1 × 10
6
 cells/ml in X-Vivo 15 and incubated overnight at 37°C, 5 % CO2, before cell 
viability was assessed by exclusion of 0.4 % trypan blue solution (Sigma). Cells were then 
plated in 1ml per well for 24-well plates. 
 
2.2.4. Terminal myeloid cell differentiation 
 
To promote differentiation to a monocyte-derived dendritic cell phenotype, CD14
+
 cell 
cultures were stimulated with granulocyte macrophage colony-stimulated factor (GMCSF; 
100 ng/ml) and IL-4 (100 ng/ml) for 5 days (both cytokines Peprotech). Mature DCs were 
then generated by adding LPS in fresh media (50 ng/ml; Sigma-Aldrich) for 2 days. To 
promote differentiation to a Langerhans cell (LC) phenotype, CD34
+
 cells were stimulated 
with transforming growth factor-beta (TGF-β; 500 ng/ml), Fms-related tyrosine kinase 3 
ligand (Flt-3L; 100 ng/ml), GM-CSF (100 ng/ml), TNF-α (2.5 ng/ml) and stem cell factor 
(20 ng/ml) (all from Peprotech) and cultured for 7 days until formation of characteristic cell 
clusters was observed. Immature LCs were then stimulated with LPS (500 ng/ml) for 
24 hours to facilitate maturation. 
  
2.3. CELL CULTURE SYSTEMS IN VITRO 
 
2.3.1. Fibroblast cell culture 
 
Human foreskin fibroblasts (HFF) (ATCC
®
 #SCRC-1041) were maintained in 175 cm
2
 
culture (T175) flasks in DMEM-10 and incubated at 37°C in a humidified 5 % CO2 
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atmosphere (37°C, 5 % CO2). Confluent cultures were passed every 4-5 days by washing cells 
in phosphate buffer solution (PBS) and adding 4 mL Trypsin-EDTA (0.5 g Trypsin, 0.2 g 
EDTA, 0.85 g NaCl/L) to promote detachment. After incubation at room temperature (RT) for 
5 mins, cells were split 1:3 into new T175 flasks and provided with 30 mL fresh media. 
 




 #CRL-3216) were kindly provided by Andrew Lever (Department 
of Medicine, University of Cambridge). Cells were maintained in 75 cm
2
 culture (T75) flasks 
in DMEM-10 and incubated at 37°C, 5 % CO2. Confluent cultures were passed every             
4-5 days by washing with PBS and adding 4 mL Trypsin-EDTA. After incubation at room 
temperature (RT) for 5 mins, cells were split 1:5 into new T175 flasks and provided with 
20 mL fresh media. 
 




 #CRL-2725) was maintained in 75 cm
2
 culture (T75) flasks in     






 cells/ml. Cultures were passed every         
5 days by splitting 1:2 into new T75 flasks and provided with 20 mL fresh media.  
 
2.3.4. THP-1 cell culture 
 
THP-1 cell lines (ATCC
®
 #TIB-202) stably expressing shRNA to human PML were kindly 
gifted by Thomas Stamminger (University Erlangen-Nurnberg, Erlangen, Germany).        






 cells/ml. Cultures were passed every 3 - 4 days by splitting 1 : 2 into new flasks and 
provided with 20 mL fresh media. 
 
2.3.5. Freezing and long term storage 
 
For long term storage, cells were pelleted by centrifugation and resuspended to a density of       
1 × 10
6
 cells per ml in freeze mix. The cell suspension was aliquoted into cryogenic vials, 
which were stored in a Mr. Frosty ™ Freezing Container (Nalgene) at -80°C overnight, 
before being transferred to a liquid nitrogen cryogenic storage system at -196°C for future 
use. Immortalised cell lines were resuscitated at regular intervals as a precaution against 






2.4.1. Virus propagation 
 
Cultured HFFs were grown to 75 % - 80 % confluence in T175 flasks and infected at a low 
MOI (0.01 FFU/cell) in 6 mL DMEM-10 for 3 hours at room temperature with gentle 
rocking. Residual media was removed and replaced with 25 mL fresh DMEM-10, and flasks 
were then incubated at 37°C, 5 % CO2. Upon 70 % infection or greater, as determined 
visually by microscopy, the media was harvested and replaced with 25 ml fresh media. 
Pooled media was centrifuged at 800 g for 20 mins to remove cellular debris, with the 
resulting supernatant stored at -80°C. This entire process was repeated every 2 to 3 days until 
all the cells had become detached from the flask, indicating non-viability. Accumulated 
frozen infectious media was thawed at 37°C and spun at 26000 g for 3 hours at room 
temperature using an Avanti J-25 Ultracentrifuge (Beckman-Coulter). Supernatant fractions 
were then discarded, and virus pellets resuspended in an appropriate volume of                       
X-VIVO
™
 15, aliquoted for seed and working stocks, and stored at -80°C.  
 
2.4.2. Virus titre determination 
 
HFFs were seeded 1 day prior to infection at a 2 × 10
4
 cells/well density in 96-well flat 
bottom plates (Corning) and incubated at 37
°
C, 5% CO2. On the day of infection, serial 
dilutions (1:2 - 1:2056) of working virus stocks were added to cells and incubated for 2 -
 3 hours at room temperature with gentle rocking. Virus solutions were aspirated and replaced 
with fresh media, and cells were incubated overnight at 37°C, 5 % CO2. Spent media was then 
aspirated off and cells were fixed in ice-cold ethanol (70%) for 3 hours at -20°C. Residual 
ethanol was removed by washing cells in PBS for 10 minutes. Cells were stained with 
100 µL/well 1 µg/mL mouse anti-HCMV IE monoclonal antibody (MAB8141, Millipore) 
prepared in PBS and incubated at RT for 1 hour. Surplus antibodies were removed by 
washing cells in PBS for 10 mins. Cells were then stained with 2 µg/mL goat anti-mouse 
Alexa Fluor
®
 594 antibody (Life Technologies) and 1 µg/mL Hoechst 33342 (Sigma-Aldrich) 
in PBS for 1 hour at RT in the dark. After the cells were washed twice in PBS, staining was 
visualised under UV and green illumination, using a Eclipse TE300 UV microscope (Nikon) 
and a C5810-01 colour chilled 3CCD camera (Hamamatsu Photonics KK). The viral titre was 
expressed in terms of fluorescent focus units per mL (FFU/mL), which may be calculated as: 
Viral titre = average no. of fluorescent foci per well × dilution factor × volume factor 
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2.4.3. Experimental virus infection 
 
To achieve the required MOI for each infection, cells were enumerated accordingly and 
aliquots of stock virus were diluted in appropriate media.  
 
Suspension cells (e.g. CD34
+
 cells, Kasumi-3 and THP-1 cell lines) were cultured for at least 
4 hours at 37°C, 5 % CO2 prior to infection. Infections were carried out in suspension using 
14 ml polypropylene tubes (BD Falcon). After pelleting by centrifugation at 300 g for 
15 minutes, cells were resuspended in 350 µL virus-containing media for 3 hours at 37°C, 
5 % CO2, with gentle agitation every 30 mins. Cells were then diluted in fresh media, 
pelleted and resuspended before being plated. 
 
Adherent cells (e.g. CD14
+
 cells and terminally differentiated myeloid cells) were cultured 
for at least 24 hours in appropriate media at 37°C, 5 % CO2 prior to infection. Media was 
removed from wells and cells washed with PBS. Virus-containing media was added to cells 
at 1.5 ml/well in 100 mm plates, 300 µL/well in 24-well plates and 50 µL in 96-well plates, 
and then incubated at room temperature for 3 hours with gentle rocking, before being 
aspirated and replaced with fresh media.  
 
2.5. MYCOPLASMA TESTING 
 
All cell lines were routinely tested for Mycoplasma contamination using MycoAlert
®
 
Mycoplasma Detection kit (Lonza). If positive results were obtained, cells would be treated 
every other day for 2 weeks with Plasmocin (InvivoGen) and then grown in antibiotic-free 
media for an additional two weeks before being confirmed mycoplasma negative. 
 
2.6. CHROMATIN IMMUNOPRECIPITATION ASSAY 
 
The following chromatin immunoprecipitation (ChIP) technique was modified from 
Bresnick et al.  Cultured cells (2 × 10
7
 per condition for CD14
+





 cells) were incubated with formaldehyde at a final concentration of 
1.0 % for 10 minutes at room temperature with gentle agitation to promote protein-DNA 
cross-linking. Glycine (0.125 mol/L) was subsequently added to quench the reaction. Cells 
were collected by scraping and centrifuging at 2,000 g for 5 minutes at 4°C and washed 
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twice in PBS. Nuclei were isolated by resuspending the pellet in ChIP cell lysis buffer for 
10 minutes on ice, followed by centrifugation at 2,000 g for 5 minutes at 4°C. Nuclei were 
then washed twice in ice-cold ChIP wash buffer and centrifuged at 2,000 g for 5 minutes at 
4°C and subsequently in ice-cold shearing buffer at 2,000 g for 5 minutes at 4°C, before 
being resuspended in 300 µL shearing buffer. Samples were sonicated using a Bioruptor
®
 
pico (Diagenode) for 9 repeated cycles of 30 seconds ‘on’ and 30 seconds ‘off’. Soluble 
chromatin was precleared by addition of 200 µL Protein A-Sepharose (50 % suspension) 
containing 1% bovine serum albumin (BSA) and sonicated herring sperm (HS) DNA at 
200 µg/m, and incubated at 4°C for 1 hour with gentle rotation. An aliquot of precleared 
chromatin was removed (input) and used in the subsequent polymerase chain reaction (PCR) 
analysis. The remainder of the chromatin was diluted with IP dilution buffer to a final 
volume of 800 µL and incubated with 5 µg of the appropriate antibody or equivalent control 
overnight at 4°C with gentle rotation. Immune complexes were collected by addition of 
60 µL of Protein A-Sepharose for 2 hours at 4°C with gentle rotation. Protein A-Sepharose 
pellets were washed twice with 500 µL aliquots of IP wash buffer 1, once with IP wash 
buffer 2, and twice with TE buffer. Immune complexes were eluted twice with 150 µL of 
IP elution buffer. RNAase A (0.03 mg/ml) and NaCl (0.3 mol/L) were added, and crosslinks 
were reversed by incubation at 65°C for 5 hours to overnight. Eluted DNA was then digested 
with Proteinase K (0.24 mg/mL) for 2 hours at 45°C, before being purified using the 
QIAquick PCR purification kit (Qiagen) according to the manufacturer’s instructions and 
collected in 30 µL DNAse-free water. Aliquots of ~2 µL were analysed by quantitative PCR 
(qPCR) using the appropriate primer pairs.  
 
2.7. PCR-BASED ANALYSIS 
 
2.7.1. Quantitative reverse-transcription PCR 
 
One-step quantitative reverse-transcription PCR (qRT-PCR) was performed to determine 
levels of viral IE and UL138 gene expression. The housekeeping gene glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) was used as an internal control to normalise the data for 
each experiment. All reactions were performed with water-only and RT-negative controls. 
 
For isolation of total RNA, cell cultures were directly harvested in in TRIzol
® 
reagent 
(Invitrogen). RNA was then purified from TRIzol
®
-lysed samples using the RNEasy Mini Kit 
(Qiagen) according to the manufacturer’s instructions, eluted in RNAse-free water, and 
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quantified using NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies). Samples 
were subsequently stored at -80°C.  
 
For SYBR Green qRT-PCR, the following primers and probes were used: IE, 5’-CGG GAC 
AGG AAG ACA TCA AGC CCG and 5’-TTG TTG CGG TAC TGG ATG GTA AA, UL138, 
5’-CAT GGC TAC GGT GGT GAA CTG and 5’-CGG GCG TCG ATC TGT TGA AAC 
CCG; GAPDH, the same set as above. Reactions were performed using QuantiTect SYBR
®
 
Green RT-qPCR kit (Qiagen) according to the manufacturer’s instructions and the samples 
amplified and detected using an ABI 7500 Fast Real Time PCR machine (95°C for 15 s and 
60°C for 45 s). 
 
Quantification of RNA was performed using the ‘comparative Ct method’ (2
-ΔΔCt
). Absence of 
a detected signal indicated that products failed to cross the threshold cycle after the maximum 
number of cycles (60) was performed.   
 
To evaluate amplification specificity, melt curve analysis was performed immediately after 
amplification by measuring the reduction in the fluorescence during a linear temperature 
transition from 60°C to 95°C at a rate of 0.5°C/sec 
 
2.7.2. Quantitative PCR 
 
Quantitative PCR (QPCR) was performed to determine levels of enrichment of epigenetic 
histone marks for various cellular and viral targets. Lyophilised desalted primers in table 
below were purchased from Sigma and reconstituted in DNAase-free water at 1 µg/ml and 
stored at -20°C. Experiments were performed using QuantiTect SYBR
®
 Green RT-qPCR kit 
according to the manufacturer’s instructions and the samples amplified and detected using an 
ABI 7500 Fast Real Time PCR machine (95°C for 15 s and 60°C for 45 s). 
 
Name Forward primer (5' - 3') Reverse primer (5' - 3') 













MIEP  TGGGACTTTCCTACTTGG CCA GGC GAT CTG ACG GTT 
TLR4 AAGCCGAAAGGTGATTGTTG CTGAGCAGGGTCTTCTCCAC 
ZNF180 TGATGCACAATAAGTCGAGC TGCAGTCAATGTGGGAAGTC 
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2.8. LUCIFERASE REPORTER ASSAY 
 
2.8.1. Transfection of Kasumi-3 and THP-1 cell lines 
 
Kasumi-3 and THP-1 cell lines were plated at 1 - 2 × 10
6
 cells/well in 6-well culture plates 
and incubated overnight at 37°C, 5 % CO2 prior to transfection. Cells were co-transfected with 
an effector expression vector (either LUNA, GATA-2 or both) along with a luciferase reporter 
plasmid (either pGL3-UL144 or pGL3-LUNA) in a 2 : 1 / effector : reporter or 1 : 1 : 1 /             
effector : effector : reporter ratio, each totalling 1.50 µg DNA. Transfections were performed 
with the V-001 program using a Nucleofector
™
 2b device (Amaxa) in conjunction with 
Nucleofector
®
 Kit R (Amaxa) according to the manufacturer’s instructions and cells were 
incubated for 48 hours at 37°C, 5 % CO2. 
 
2.8.2. Luciferase assay 
 
Cellular lysates for assaying were prepared using the luciferase assay system (Promega) 
according to the manufacturer’s instructions. Briefly, cells were washed in PBS and then 
resuspended in cell culture lysis reagent. 20 µL lysate from each condition was then plated 
into 96-well luminescence plates (Greiner) in duplicate format. Luciferase expression 
activity was subsequently measured using a GloMax
®
-Multi Microplate Multimode reader 
(Amaxa), in which 100 µL luciferin substrate was delivered to each well and the 
luminescence produced measured after a 1 second delay with an integration time of 
10 seconds.  
 
2.9. CO-IMMUNOPRECIPITATION ASSAY 
 
2.9.1. Transfection of HEK293T cell line 
 
HEK293T cells were seeded into 100mm dishes and cultured for at least 4 hours at 37°C, 
5 % CO2 prior to transfection. Once cells had reached ~70 % confluency, they were                      
co-transfected with LUNA and GATA-2 effector expression vectors in a 1:1 ratio, totalling 
1.50µg DNA. Transfections were performed using TransIT®-293 transfection reagent             
(Mirus Bio) according to the manufacturer’s instructions, and cells were then incubated for 





The following procedure for co-immunoprecipitation (co-IP) experiments was adopted from 
ImmunoCruz
™
 IP/WB Optima E system (Santa Cruz Biotechnology, Inc.) with modifications. 
Briefly, whole cell lysate was prepared by washing cells twice in PBS, followed addition of 
1mL ice-cold RIPA buffer with repeated aspiration for 10 minutes. Cellular debris was 
removed by centrifuging at 10000 g at 4°C for 15 minutes, and transferring the supernatant to 
new 1.5 ml Eppendorf tubes. Antibody agarose conjugates were formed by incubating 
5µL rabbit polyclonal anti-FLAG
®
 antibody (F7425; Sigma) with 50 uL suspended (25 % v/v)     
IP matrix in 500 µL PBS. 200 µL of clarified lysate with then incubated with the above 
complexes overnight at 4°C with gentle rotation. IPs were then washed three times in 750 µL 
lysis buffer for 20 minutes at 4°C before agarose beads were incubated in 75 μl of      
2 × SDS-PAGE sample buffer containing 5 % β-mercaptoethanol at 85°C for 10 min to elute 
proteins. 
 
2.9.3. Western blotting 
 
Samples were boiled at 95°C for 2 mins before being loaded in equal amounts (20 µL) on a 
12 % bis-acrylamide Resolving gel overlaid with a 12 % Stacking gel. Proteins were 
separated by electrophoresis using SDS-PAGE, before being electroblotted on to Hybond 
nitrocellulose membranes (Amersham) using Transfer buffer. Samples were than pre-treated 
in blocking solution (5 % milk in 1 × PBS) at room temperature for 1 hour, then incubated 
with primary rabbit anti-GATA-2 antibody (Cell Signalling Technologies) diluted 1 : 1000 in 
blocking solution overnight at 4°C. Primary antibodies were detected using HRP-conjugated 
rabbit anti-mouse IgG antiserum (Santa Cruz) diluted 1 : 2000 in blocking solution at room 
temperature for 1 hour. All antibody incubations were followed by 3 washes using 
0.1 % Tween-20 in PBS. Detection of proteins was carried out using Chemiluminescence 
(ECL, Amersham) according to the manufacturer’s instructions, followed by 







2.10. INDIRECT IMMUNOFLUORESCENCE 
 
2.10.1. Specimen preparation  
 
Kasumi-3 (stably transfected) and THP-1 cells were suspended in solution and measured by 
trypan blue dye exclusion using a haemocytometer. Approximately 3 - 4 × 10
4
 cells in 200 µL 
PBS were cytospinned onto polylysine-coated glass slides at 500 rpm for 5 min. Each slide 
was then fixed in 4% paraformaldehyde (PFA) for 10 minutes at room temperature, before 
being washed and maintained in PBS. Monocytes were washed in PBS and then fixed in 4 % 
paraformaldehyde for 10 minutes at room temperature, before being washed and maintained in 
PBS. 
 
2.10.2. Staining procedure 
 
Fixed cells were permeabilised in 0.1 % Triton-X-100 for 2 minutes before being washed in 
PBS. Cells were subsequently incubated with mouse monoclonal anti-FLAG M2 (1 : 500; 
Sigma) and goat anti-PML (1:500, clone N19; Santa Cruz Biotechnology) for 1 hour. After 
washing in PBS, slides were incubated with donkey anti-goat Alexafluor 488 nm and rabbit 
anti-mouse Alexafluor 594 nm antibodies (1:1000; Merck Millipore) for 1 hour and then 
visualised as described above.  
 
2.11. GENOME FLUORESECENT IN SITU HYBRIDISATION 
 
Genome fluorescent in situ hybridisation (FiSH) experiments were performed by Matthew 




 cells were infected and 
cultured on glass coverslips for 7 days prior to processing. Briefly, cells were fixed in 4 % 
PFA, and following washing in PBS, were incubated in hybridization buffer (50 % 
formaldehyde / 10% dextran sulphate in PBS) for 1 hour at 37°C. Cells were then incubated 
with a fluorescently labelled HCMV cosmid DNA probe (Cy3-dCTP) spanning the major 
immediate early region for 90 seconds at 95°C in hybridization buffer followed by an 
overnight incubation at 37°C. Two washing steps in 2 × saline sodium citrate buffer (each 
5 mins; at 60°C) were followed by a wash in PBS at room temperature and then stained, as 




2.12. DESUMOYLATION / “SUMO-CHOP” ASSAY 
 
A SUMO-CHOP assay kit (Lifesensors, Malvern, PA) was used to identify isopeptidase 
activity. Briefly, following cleavage of a SUMO3-reporter system by a candidate 
isopeptidase activity, the reporter becomes free to act upon its substrate, thereby generating a 
fluorescent signal which can be measured to quantify the level of isopeptidase activity. 
Recombinant LUNA was generated from BL21 bacteria transfected with either 
PET102UL82as or pCMV-Tag2b-FLAG-g233c using previously published methods
263
. 




Unless otherwise stated, a comparison of the means were performed using unpaired,                 
two-tailed Student’s t test with p values reported or stated as being not significant (NS). 
Where multiple comparisons were made, one-way ANOVA tests were performed followed 





















HCMV is the prototypical member of the β-herpesvirus subfamily. Like all herpesviruses, 
HCMV establishes latency as a hallmark of infection, which is integral to promoting lifelong 
persistence as well as becoming a widespread human pathogen. While most acute infections 
with HCMV are asymptomatic in healthy individuals, they are otherwise associated with 
opportunistic disease in those with immature or compromised immune systems, such as 
neonates or recipients of organ transplantation, respectively
299,300
. Therefore, in addition to 
primary infection, latent virus and their ability to reactivate represent a serious clinical threat 
to vulnerable patient populations, underscoring the importance of understanding the 
mechanisms that govern this major life cycle process.  
  
Cells of the early myeloid lineage, such as CD34
+
 progenitors and CD14
+
 monocytes, 
represent major sites of HCMV latency in vivo
209
. During latency, the virus genome is 
maintained extrachromosomally as a circular episome in the concomitant absence of lytic gene 
expression. Importantly, the expression of major IE (MIE) genes IE1 and IE2, which are the 
main viral transactivators responsible for initiating the lytic cascade of virus gene expression, 
is suppressed. This is maintained by specific post-translational histone modifications around 
the MIE promoter (MIEP), amounting to the formation of repressed chromatin
170
. In latently 
infected CD34
+
 cells,   the MIEP has been found to be associated with heterochromatin 
protein-1 (HP-1), along with the presence of repressive histone marks and absence of histone 
acetylation, thus reflecting a closed chromatin configuration
219
. Indeed, this configuration has 




. However, upon 
differentiation of these cells to a mature phenotype, associated changes in the nuclear 
environment results in activation of the viral MIEP and the reactivation of productive 
replication. 
 
The silencing of HCMV DNA through chromatinisation and epigenetic histone modifications 
are not only observed during latency, but also feature during lytic infection of permissive cells 
as part of an intrinsic immune response
181
. During infection with a number of nuclear-
52 
replicating DNA viruses, including HCMV as well as other herpesviruses, discrete subnuclear 
structures, termed ND10, rapidly become localised to sites of deposited viral genomes
301
. 
These structures resemble dynamic clusters of protein found within the nucleoplasm, but are 
primarily defined by the presence of core constituent proteins PML, hDaxx and Sp100
177
. 
Several studies have demonstrated that these major ND10 components independently 
contribute to the silencing of herpesvirus gene expression, giving rise to the notion that ND10 
serve to restrict viral replication by generating a transcriptionally repressive environment 
around incoming viral DNA
178,186,197,302
. Notably, hDaxx is implicated in generating a 
repressed chromatin structure around the HCMV MIEP at very early times post-infection, 
thereby inhibiting IE gene expression
185
. Yet, unsurprisingly, most, if not all herpesviruses, 
encode discrete factors to overcome the cellular restriction imposed by ND10, which often 
leads to ND10 becoming disrupted as infection proceeds. Thus, with respect to HCMV, the 
tegument-derived pp71 protein facilitates the proteasomal degradation of hDaxx, whereas the 
IE1 protein induces the complete dispersal of ND10 by selectively modifying PML, the main 
scaffold protein for ND10 assembly
185,197,198,303
. In both cases, the respective function of each 
viral factor correlates with efficient IE gene expression and subsequent productive replication. 
 
While it is clear that lytic HCMV infection results in the potent disruption of cellular ND10,   
little is known about what happens to ND10 in the context of latency. Presently, it is 
understood that viral pp71 is sequestered in the cytoplasm of latently infected cells, which thus 
prevents it from relieving the transcriptional repression of IE genes mediated by ND10-
associated protein hDaxx
304
.  Since the MIEP is known to adopt a repressed chromatin 
conformation during latent infection, as it also appears to do during the ‘pre-IE’ stages of lytic 
infection, it has been suggested that the inability to antagonise the repressive functions of 
ND10 during latent HCMV infection may aid in their general capacity to form silenced 
chromatin over latent viral genomes, and in so doing, contribute to latency establishment
305,306
. 
Therefore, the primary aim of this investigation was to determine what effect HCMV had on 











3.2.1. ND10 structures are disrupted during latent HCMV infection 
 
Cellular ND10 structures are represented by discrete foci appearing within the 
interchromosomal space of the nucleus. They are found in virtually all cell types, with their 
diameter ranging from 0.2 to 1 µm and frequency varying from a minimum of between three 
to ten, up to a maximum of 15 to 30, depending on cell type and status
37,307,308
. Discerning 
microscopically between individual ND10 foci is best achieved through examination with a 
very high magnification lens, which usually necessitates the use of glass slides that provide 
minimal refraction of light. Unfortunately, cells used throughout project were often difficult to 
mount successfully on to coated and uncoated glass slides, and as a result, plastic had to be 
used instead. Because plastic is incompatible with the effective use of very high magnification 
objectives, I chose to define cells as having non-disrupted (intact) ND10 if a minimum of five 
discrete foci were present and disrupted ND10 if under five. 
 
The PML protein is a major constituent component of ND10 that plays an important role in 
their assembly and maintenance. Since PML is critical for the structural integrity of ND10, 
loss of PML consequently leads to a dispersal of ND10 foci
309
. This is well established for a 
number of cell lines used to model lytic infection of HCMV, but is also clearly the case for 
myeloid cells, which are known to routinely establish latent HCMV infection
220
. To this end, 
shRNA-mediated PML-knockdown of myelomonocytic THP-1 cells show clear disruption of 
ND10 (Figure 3.1). 
 
Early myeloid progenitors constitute sites of latent HCMV carriage in vivo
238
. Previous reports 
support their use as models of experimental latency, in which following infection, there is an 
absence of IE gene expression that correlates with a lack of infectious viral spread
237
. To 
evaluate the disruption of ND10 bodies during latency, primary CD34
+
 stem cells were also 
infected with the HCMV reference strain Merlin. Similarly, primary CD14
+
 monocytes were 
also infected with GFP-expressing virus of the low-passage strain TB40-BAC4. Here, an 
opportunity should be taken to note that any analysis of global changes in HCMV-infected 
cells of the myeloid lineage is marred by the low frequency at which the virus appears to 
infect these cells in vitro unless very high MOI are used
310
. However, previous analysis of 
CD34
+
 cells carrying HCMV genome following experimental latent infection with               
low-passage HCMV isolates at MOI = 5 (based on fibroblast infection) have shown that up to 
60-70 % of cells carry the HCMV genome by in situ hybridisation assays (S. R. McGregor 
54 
Dallas & J. Sinclair, unpublished observations)
311
. Hence, I reasoned that this level of 
experimental latent infection should still result in global phenotypic changes that would be 
discernible. FISH analysis, performed using a fluorescent Cy3-labeled HCMV cosmid DNA 
probe, showed that virally-infected CD34
+ 
cells were devoid of ND10 compared to uninfected 
bystanders, consistent with both a demonstrable lack of PML staining and cellular 
enumeration (Figure 3.2). Likewise, using immunofluorescence microscopy, the same ND10 
disrupted phenotype was observed in latently infected CD14
+ 
monocytes relative to uninfected 

























































































Figure 3.1. Depletion of PML prevents formation of ND10 structures in myeloid 
cells  
(A) THP-1 cells stably expressing shRNA to PML (siPML) or inactive shRNA (siC) 
were fixed and stained for PML, then analysed by immunofluorescence microscopy 
(magnification; × 100). (B) The number of ND10 positive or negative cells were 
enumerated using ImageJ software. Bars represent averages of 5 fields of view of 
































































































































Figure 3.2. HCMV-infected CD34
+
 myeloid cells show disrupted ND10   
Primary CD34
+
 cells were infected with wild type Merlin at MOI = 5 for 7 days to 
promote latency establishment. (A) Infected cells were identified by genome FISH (red) 
and subsequently stained for PML (green) as an indicator of ND10 integrity 
(magnification; × 100). (B) The number of infected ND10 positive or negative 
CD34
+
 cells were scored from 10 fields of view at 7 days post infection with wild type 







































































Figure 3.3. HCMV-infected CD14
+
 monocytes show disrupted ND10.   
Primary CD14
+
 monocytes were infected with wild type SV40-GFP-TB40-BAC4 at 
MOI = 5 for 3 days to promote latency establishment. (A) Cells were stained using         
anti-GFP antibody for GFP-tagged strain TB40-BAC4 (green) and PML (red); hoechst 
DNA staining (blue) indicates position of nuclei (magnification; ×100). Yellow arrows 
point to a successfully infected cell exhibiting disruption of ND10 by PML staining.   
White arrows point to uninfected cells containing intact ND10. (B) The relative number of 
latently infected (GFP+) or uninfected bystander cells (GFP-) in the population coincident 
with intact ND10 were enumerated using ImageJ software. Bars represent averages of 



































3.2.1. Deletion of the IE1 coding region does not prevent ND10 
disruption in latently infected cells 
 
HCMV proteins pp71 and IE1 have been identified as viral factors responsible for 
overcoming the negative regulatory effects of ND10 during lytic infection. One contributing 
factor to latent infection has been posited to be the failure to deliver viral pp71 to the nucleus 
in non-permissive cell types
304
. However, by contrast, the expression of IE1 has been detected 
in models of experimental latency, albeit only transiently and weakly
248
. Notably, it has been 
observed that the IE1 exon 4 mRNA is transcribed during latent infection of haematopoietic 
progenitor cells, resulting in the latent expression of a distinct IE1 protein species
295
.  
Previous research has shown that the exon-4 segment of the IE1 coding sequence is important 
in conferring the ability of IE1 to induce loss of SUMOylated PML that leads to ND10 
disruption
198
. Consequently, despite its classification as a lytic gene product critical for 
productive infection, it can be argued that IE1 may play a role in mediating ND10 disruption 
during latency. To evaluate this possibility, primary CD14
+
 monocytes were infected using 
IE1 mutant TB40-BAC4 viruses, which were then assayed for ND10 disruption. Consistent 
with previous results, deletion of IE1 or of its corresponding exon-4 segment did not prevent 























































































































































Figure 3.4. IE1 does not prevent disruption of ND10 in context of latent infection 
CD14
+
 monocytes were infected with eGFP-expressing TB40-BAC4 wild type, IE1 
deletion (∆IE1), IE1 exon-4 deletion (∆IE1exon4) viruses at MOI = 5 for 3 days to 
promote latency establishment. (A) Cells were stained for GFP (green), PML (red) or 
nuclei (blue) (magnification; × 100). Yellow arrows point to a successfully infected cell 
exhibiting disruption of ND10 by PML staining. White arrows point to uninfected cells 
containing intact ND10. (B) The number of ND10 positive or negative cells were 
enumerated using ImageJ software. Bars represent averages of 5 fields of view of 100 








































3.2.2. Direct expression of LUNA promotes disruption of ND10 in 
undifferentiated myeloid cells 
 
Research conducted by our laboratory has sought to address the functions of a number of 
HCMV latency-associated gene products during latent infection. The HCMV LUNA protein is 
an example of one such latent viral gene product whose direct effects on the latently infected 





While investigating the role of LUNA under conditions of viral reactivation and lytic 
infection,  Emma Poole in collaboration with Matthew Reeves (University College London, 
UK), observed that the isolated expression of LUNA in fibroblasts – which are permissive for 
lytic infection – caused them to become devoid of ND10 (Poole et al. under review). Thus, 
LUNA, like HCMV lytic IE1, may be involved in disrupting ND10 structures. Given its 
latency-associated expression, this means LUNA could be the factor responsible for 
promoting the disruption of ND10 in undifferentiated myeloid cells. Hence, to assess the 
potential role of LUNA in mediating ND10 disruption under conditions of latency, transient 
transfection assays were performed to express the protein in isolation and monitor its effects 
accordingly. Kasumi-3, a CD34
+
 undifferentiated leukaemia cell line, was used as a tractable 
model for this study as not only was it transfectable, but it had also been shown in previous 




Direct expression of LUNA in Kasumi-3 cells strongly coincided with a lack of distinct PML 
foci, arguing for the existence of its role in disrupting ND10 (Figure 3.5). Moreover, the 
images indicate a predominantly nuclear localisation of the LUNA protein. However, this is 
not consistent with previously published data that shows LUNA localising to the periphery of 
the nucleus in latently infected CD14
+
 monocytes one day post-infection
266
. To that end, it is 
possible that the cellular localisation of LUNA may be influenced by different cell types of 
haematopoietic origin, but also the context by which it is expressed, either directly or through 



































































Figure 3.5. Myeloid cells transfected to express LUNA exhibit disrupted ND10 
The early myeloid cell line, Kasumi-3, was transiently transfected with expression 
plasmids encoding wild type FLAG-LUNA fusion protein. (A) 48 hours post 
transfection, cells were cytospinned and stained for LUNA (green), PML (red) or nuclei 
(blue) (magnification; × 100). Yellow arrows point to a successfully infected cell 
exhibiting disruption of ND10 by PML staining. White arrows point to uninfected cells 
containing intact ND10. (B) The number of transfected ND10 positive or negative cells 
were enumerated using ImageJ software. Bars represent averages of 5 fields of view of 




































































Taken together, these results demonstrate that ND10 are disrupted during HCMV latency.   
Nuclear PML foci resembling intact ND10 are absent in early myeloid cells infected with         
wild-type phenotype viruses (Figures 3.2 and 3.3), reflecting similar observations made in PML 
knockdown cells (Figure 3.1). Additionally, the finding that IE1-null viruses failed to prevent 
the same effect from occurring excludes the possibility of this factor being responsible for 
mediating ND10 disruption in the latently infected cell (Figure 3.4). However, evidence points 
to a potential role for the viral LUNA protein in mediating disruption of ND10, notably, under 
conditions that support latency establishment in vitro where it is otherwise known to be 
expressed (Figure 3.5).  
 
Given that the disruption of ND10 are essential for robust HCMV lytic gene expression and 
productive replication, the apparent loss of these structures during HCMV latency is striking. 
Indeed, it does not appear that ND10 are required for the maintenance of HCMV latency. 
Although ND10 have previously been suggested to contribute towards latency establishment 
by facilitating the silencing of incoming viral genomes, it is more likely that early myeloid 
cells inherently unable to support MIEP activity due to the differentiation status of the cell and 
the relative absence of positive effectors of the MIEP. Therefore, MIEP suppression during 
latency involves a plethora of cellular factors beyond those described thus far in the context of 
ND10-mediated suppression
102
. Whichever is the case, major components of ND10, such as 
PML, hDaxx and Sp100, appear unlikely, in themselves, to be the main cause of MIEP 
suppression during latency in view of recent evidence demonstrating that depletion of each of 




To strengthen the findings made above, further evidence regarding the disruption of ND10 
should be brought to bear. Though subsequent investigations detailed throughout this report 
make use of LUNA mutant viruses, the current data does not indicate whether the disruption 
of ND10 in the context of latent infection is facilitated by events occurring downstream of 
PML gene expression. This can be addressed by appending the above analyses with western 
blotting of PML protein. One would predict that levels of PML should remain similar to 
uninfected controls during latent infection, but should otherwise be completely absent during 









Cellular ND10 structures have increasingly been shown to act as an intrinsic line of defence 
that restricts lytic HCMV infection by targeting incoming viral DNA for transcriptional 
repression
37
. However, this antiviral response is rapidly counteracted by a number of       
virally-encoded proteins, resulting in either the degradation or relocalisation of ND10 
components
181
. Indeed, their roles in disrupting the repressive functions of ND10 have been 
shown to be important for enabling efficient viral gene expression and productive viral 
replication in permissive cell types. Nevertheless, as demonstrated earlier, latently infected 
cells are also similarly devoid of ND10, which appears to be linked to the expression of the 
latency-associated viral LUNA protein. Because this particular finding argues for a relief of 
ND10-mediated repression, it is thus possible that LUNA might be able to affect virus gene 
expression during HCMV latency. Consequently, the aim of this investigation was to examine 




4.2.1. Viral growth kinetics of recombinant Merlin strain mutants show 
no significant differences  
 
To evaluate the function of LUNA during latent infection, a LUNA translation mutant was 
created through BAC recombineering of the Merlin backbone. Notably, although a stop codon 
was introduced to prevent LUNA expression, this did not disrupt the UL82 gene on the 
complementary DNA strand.  
 
As a preliminary investigation, the growth of the LUNA-deficient virus was assayed for 
normal productive replication under lytic conditions in order to eliminate the possibility of any 
resulting phenotype observed during latency being linked to a defect in lytic replication. 
Consistent with previously published data, the deletion of LUNA did not majorly impact on 
65 
the growth of the virus in human fibroblast culture, which is otherwise permissive for lytic 










































Figure 4.1. LUNA deficient viruses showed no significant defects in lytic viral growth 
Wild type (WT), LUNA deletion or revertant viruses were generated by BAC 
recombineering using the Merlin backbone, which expresses a GFP-UL32 fusion protein. 
HFFs were plated at equal numbers and were subsequently infected at an MOI of 0.01. 
Viral growth was then measured over 10 days. Supernatants were titred for infectious 
virus production every 2 days by overlaying onto a monolayer of fibroblasts and 




























4.2.2. LUNA is required for efficient viral gene expression during latent 




To address the impact of LUNA on virus gene expression during HCMV latency, RNA 
analyses were performed on undifferentiated CD34
+
 cells infected with LUNA-deficient virus. 
Specifically, levels of viral UL138 and IE1 gene expression were assayed by RT-qPCR using 
total RNA as a target. UL138 is a latency-associated gene product, which has been shown to 
be important for establishing latency
313
. Recently published data suggest that UL138 directs 
repression of IE gene expression by preventing the removal of histone methylation marks at 
the MIEP
285
. By contrast, IE1 is a well-established MIE gene product, which is responsible for 
inducing the lytic cascade of virus gene expression
143
. Although, the latency-associated 
transcription programme is now thought to be far more complex than first thought, it is 
universally accepted that IE1 is poorly expressed in all natural and experimental models of 
latency, such that measurement of this transcript, in conjunction with UL138, serves as a 




In general, analysis of latently infected myeloid cells characteristically gives levels of UL138 
RNA higher than IE1 RNA (i.e. UL138/IE1 ratio is much greater than 1). In contrast, during 
lytic infection IE1 RNA level are substantially higher than UL138 level
215,315
. Consistent with 
this, CD34
+
 cells infected with WT Merlin showed levels of UL138/IE1 RNA entirely 
consistent with a latent infection (Figure 4.2A). Moreover, an approximate four-fold and     
ten-fold decrease, respectively, in the levels of both UL138 and IE expression, were observed 
during latent infection with LUNA deletion virus compared to wild type viruses (Figure 4.2B). 
This finding is consistent with the view that LUNA is involved in regulating viral          
latency-associated gene expression. However, it also suggests that residual IE1 expression 
































































stem cells latently infected at MOI = 5 with wild 
type (WT), revertant (Rev) and LUNA deletion (LUNA Del) at 7 days post infection were 
analysed for UL138 and IE1 gene expression by RT-qPCR. All samples were normalised 
to GAPDH. (B) Relative expression of UL138 and IE1 gene expression. Data presented 
are pooled from 3 biological replicates, with bars representing the averages of triplicate 
measurements, and standard deviations shown. Statistical analysis was by one-way 
analysis of variance (ANOVA) (UL138: F = 43.30, degrees of freedom, d.f. = 11,                
P < 0.0001; IE: (F = 1073.27, d.f. = 11, P < 0.0001), using a post-hoc Tukey's multiple 
comparison test. Results generated from LUNA knockout viruses are significantly 
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p<0.0001 
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 cells serve as a robust model for supporting experimental HCMV 
latency, they are expensive to obtain on a regular basis. For this reason, more easily obtainable 
types of primary myeloid cells, capable of supporting latency, were used to further evaluate 
the role of LUNA. 
 
To validate primary CD14
+
 monocytes as an alternative cell model for this investigation, 
monocytes infected with wild-type Merlin virus were co-cultured with fibroblasts to monitor 
production of infectious virus. Prior to infection, monocytes were either left untreated 
(undifferentiated) or pre-treated with prednisolone (causing myeloid differentiation)
316
. After           
7 days post-infection, no viral UL32-GFP-expressing foci were detected in co-cultures 
containing undifferentiated monocytes, indicating successful latency establishment; however, 
in those that had been treated with prednisolone, evidence of infectious viral spread was 
observed, consistent with the acquisition of a permissive phenotype that accompanies cellular 














































































Figure 4.3. Undifferentiated CD14
+
 monocytes support latent HCMV infection 
CD14
+
 monocytes isolated from healthy individuals were plated at 5×10
5
 cells per well 
and cultured for 4 days in the presence of prednisolone (differentiated) or under mock 
conditions (undifferentiated) prior to infection with wild type UL32-GFP-tagged Merlin 
virus at MOI = 5. (A) Cells were visualised for GFP expression at 5 and 7 days            
post-infection. (B) The number of GFP positive or negative cells were enumerated using 
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4.2.2. LUNA is required for efficient viral gene expression during         




Earlier, I showed that LUNA appears to be required for efficient viral gene expression during 
HCMV latency in CD34
+
 cells. To determine if this CD14
+
 model of experimental latency 
also demonstrates a similar requirement for LUNA, total RNA was extracted from 
CD14
+
 monocytes infected with LUNA deficient virus, then assayed for UL138 and IE1 
expression as before. Consistent with the previous trend, an approximate five-fold decrease in 
the levels of both UL138 and IE gene expression were observed during latent infection of 
CD14
+



















































































(A) RNA isolated from CD14
+ 
monocytes plated at 5×10
5
 cells per well latently infected 
with revertant (Rev) and LUNA deletion (LUNA Del) viruses at MOI = 5. After 3 days 
post infection, the cells were harvested and analysed for IE1 gene expression by             
RT-qPCR. All samples were normalised to GAPDH. (B) As above, except for UL138 
expression. Data presented are pooled from 3 biological replicates, with bars representing 
the averages of triplicate measurements, and standard deviations shown. Student’s t test 
was used to determine the significance of differences between gene expression of Rev and 

























































4.2.1. LUNA-associated changes in viral gene expression correlate with 
histone protein modifications during HCMV latency 
 
To provide a possible molecular explanation for the differences in levels of viral gene 
expression observed during latent infection with HCMV, ChIP analyses were performed in 
latently infected monocytes to evaluate the epigenetic landscape surrounding                   
latency-associated viral gene promoters in particular. The viral latency-associated genes 
UL144 and LUNA itself were chosen as candidates for interrogation, owing to the fact that 
their promoter sequences had already been functionally characterised
282
. Both UL144 and 
LUNA are important for the efficient establishment of latency in an in vitro system. Moreover, 
although UL144 is known to be expressed in a strain-dependent manner, Merlin virus is 




Briefly, with respect to epigenetic profiling, the ‘nucleosome-code’ hypothesis posits that the               
post-translational modification of histones is associated with the regulation of gene 
expression, either by relaxing or condensing the local chromatin structure to activate or repress 
transcription, respectively
166
. For instance, promoters of recently transcribed or active genes 
are denoted by the presence of histone H3 trimethylated at lysine 4 (H3K4me3), which is 
otherwise absent from silenced genes. By contrast, repressed genes and heterochromatin are 
linked to the presence of H3K9me3. Measuring H3K4me3 enrichment at the host gene TLR4 
and H3K9me3 at ZNF180 serve as positive controls for activatory and repressive marks, 
respectively, in myeloid cells.    
 
In keeping with the transcriptional data shown above, observable changes in histone 
modification patterns around latency-associated promoters appeared to reflect their own 
promoter activity. Specifically, LUNA expression during a latent infection coincided with the 
acquisition of markers of transcriptional activation over the promoters of latency-associated 
viral genes (Figure 4.5A). Additionally, a converse trend showing a loss of markers of 
transcriptional repression from the same promoters was observed in the presence of LUNA, 
however, no statistical significance was ascertained for the UL144 promoter and 

































































Figure 4.5. LUNA promotes changes in histone modification patterns during latency  
Chromatin immunoprecipitation assays with anti-histone H3 trimethylated at lysine 4  





 cells latently infected with revertant (Rev) or LUNA deletion (LUNA Del) virus at 
MOI = 4. Samples were amplified using primers targeting known regions in the LUNA 
promoter and UL144 promoter and expressed as a logarithmic function over the Input. 
H3K4me3 enrichment is represented in A. TLR4 was used as a positive control candidate 
for H3K4me3 enrichment. H3K9me3 enrichment is represented in B. ZNF180 was used a 
positive control candidate for HEK9me3 enrichment. Bars represent averages of triplicate 
analyses from two independent experiments, with standard deviation shown. Student’s 
t test was used to determine the significance of the differences in histone enrichment 
between infections with Rev and LUNA Del viruses. Points with no error bars represent 














































LUNA promoter UL144 promoter UL138 promoter
A. H3K4me3 enrichment (activatory) 
p<0.05 p<0.05 p<0.05 
B. 
125073 
H3K9me3 enrichment (repressive) 
p<0.05 p=NS 
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4.2.2. LUNA is required for efficient viral reactivation during latent 




So far, this Chapter has shown that the expression of LUNA is required for efficient              
latency-associated viral gene transcription during latent infection. Because viral gene 
expression during latency is essential for maintaining the latent phenotype, it is plausible that 
LUNA may contribute towards the process of latency by promoting gene expression in the 
latently infected cell. To evaluate this further, our laboratory performed an experiment in 
collaboration with Matthew Reeves (UCL) to examine whether LUNA was required for viral 




 cells were latently infected with LUNA-deficient Merlin virus and 
subsequently differentiated to dendritic cells 7 days post-infection. Cells were then 
stimulated with LPS to induce reactivation, and in turn analysed for IE gene expression by 
RT-qPCR and assayed for infectious virus production by co-culturing with human 
fibroblasts. It was observed that the induction of IE gene expression was impaired in cells 
infected with LUNA deletion mutants and that this was consistent with a reduction of 
reactivation of infectious virions (Figure 4.6A and 4.6B). Together, this indicates that LUNA 









































































Figure 4.6. LUNA is required for efficient reactivation of HCMV following 




 cells, plated at 1×10
5
 cells per well, were latently infected with WT and 
LUNA Del viruses at MOI = 5. At 3 days post-infection, cells were differentiated to 
immature dendritic cells by the addition of differentiation cytokine media. At 10 days   
post-infection, cells were then incubated with LPS for 24h to promote dendritic cell 
maturation and hence reactivation. Cells were then analysed for IE gene expression by   
RT-qPCR (A) or co-cultured with HFFs and assayed for infectious virion production (B). 
Bars represent averages of triplicate analyses from two independent experiments, with 
standard deviation shown. Student’s t test was used to determine the significance of the 
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Together, these findings demonstrate that the HCMV LUNA protein plays a role in regulating 
viral gene expression during latency. This is evidenced by the reduced detection of viral gene 
transcripts in models of experimental latent infection using viruses deficient in LUNA 
(Figures 4.2 and 4.4). The observed differences in viral gene expression also coincided with 
corresponding changes in the chromatin structure of latency-associated genes, suggesting a 
possible molecular basis for their regulation (Figure 4.5). Moreover, on a functional level, it 
also appears that LUNA is required for enabling viral reactivation from latency (Figure 4.6). 
 
Since LUNA appears to contribute towards the control of viral gene expression during latency, 
this fits with previously published work demonstrating its importance in maintaining latent 
genome carriage in myeloid cells. Notably, UL138 is a latency-associated gene product whose 
expression is required for maintaining virally-infected cells in a latent state
260
. When LUNA is 
absent during latency, the expression of UL138 drops significantly as a result, which supports 
LUNA having a putative role in latency establishment. Additionally, levels of MIE gene 
expression were also positively upregulated by LUNA during latency. This is surprising as in 
latently infected cells, the MIEP (which controls expression of IE1 and IE2) assembles into 
repressed chromatin through a process dependent on the UL138 gene product
285
. Given that 
LUNA promotes the disruption of ND10, which are known intrinsic repressors of HCMV 
IE gene expression, one hypothesis is that LUNA may augment the activity of the MIEP by 
affecting the overall balance of transcriptional regulators which target it. Thus, it is also 
conceivable that by allowing the MIEP to be maintained in a more poised state for 
transcriptional activation, LUNA may also be required for latent genomes to reactivate 
efficiently, once a sufficient stimulus for reactivation is given. Work performed in 
collaboration with Matthew Reeves has confirmed this, whereby latently infected CD34
+
 cells 
fail to efficiently express IE genes or undergo lytic replication following terminal 
differentiation to mature DCs when LUNA is not present. 
 
Data obtained from ChIP analysis also show that LUNA can affect the chromatin landscape 
over viral genes during latency. Clearly, this suggests a potential epigenetic mechanism by 
which LUNA can affect levels of viral gene transcription. It is therefore plausible that the 
expression levels of gene transcripts for whose promoters were not assayed by ChIP would 
also be similarly affected in latently infected cells when LUNA is absent. Notably, the finding 
that the promoters of latency-associated genes showed a clear switch between the enrichment 
77 
of repressive (H3K9me3) and active (H3K4me3) marks points to a dynamic regulation and it 
would interesting to further evaluate the which proteins or chromatin modifiers bind to those 
promoters and the impact LUNA has in determining their presence or absence.  
 
An oversight worth noting in this investigation is the absence of available data demonstrating 
equal infectivity of each virus, particularly in support of results shown in Figures 4.2 and 4.4. 
Understandably, this impacts on the interpretation of the role of LUNA on latency-associated 
viral gene expression, whereby reduced levels of virus gene expression seen during latent 
infection with LUNA deletion virus compared to WT phenotype viruses may reflect low levels 
of latent viral genome carriage and associated gene expression, rather than lack of an 
upregulatory effect from LUNA. Although appropriate methodological steps were taken to 
ensure equal infectivity (e.g. uniform numbers of cells plated and calculating the respective 
PFUs for each experiment), data produced from an ongoing study that utilises the same virus 
materials described above has shown that equal MOI infection of myeloid cells with LUNA 





Overall, however, it remains unclear whether the totality of the effects described are driven by 
the ability of LUNA to disrupt ND10 in the latently infected cell. Despite this plausibility, 
further work is required to demonstrate whether the disruption of ND10 (by LUNA) is 
responsible for affecting changes in the local chromatin structure at the viral DNA that would 













5. Evaluating the direct impact of LUNA expression on the 




In the previous Chapter, I established that virus gene expression during latent HCMV 
infection is regulated by the viral LUNA protein. Thus, when undifferentiated myeloid cells 
become infected with LUNA-deficient viruses, fewer latency-associated gene transcripts (as 
well as IE transcripts) are detected.         
 
One of the ways in which LUNA may regulate the expression of HCMV genes is by 
stabilising nascent RNA so that levels of viral messenger transcript are maintained throughout 
the duration of infection. However, given that the expression of LUNA in the latently infected 
cell correlates with the establishment of active chromatin over the promoters of                 
latency-associated viral genes, it seems more likely that LUNA functions instead by activating 
viral gene transcription. Therefore, under latent conditions, one may hypothesise that the 
promoters of latency-associated genes would exhibit a difference in activity depending on 
whether LUNA was present or absent. As such, the aim of this investigation was to test the 
above hypothesis in order to further evaluate the role of LUNA in controlling viral gene 


















5.2.1. The myelomonocytic Kasumi-3 cell line supports HCMV latency              
in vitro 
 
Before assessing the ability of LUNA to regulate viral gene expression at the transcriptional 
level, it was first necessary to develop a tractable model system with which to study such 
effects of LUNA in vitro. Much of the data I have presented so far, in respect of functionally 
characterising LUNA, has been obtained using primary myeloid cells that are fully capable of 
supporting HCMV latency. However, these cell types are difficult to manipulate by molecular 
techniques (e.g. transfection), rendering them unsuitable for use in this study. Therefore, the 
CD34
+
 haematopoietic progenitor cell line Kasumi-3 was selected as an alternative model, as 
these cells are easily manipulatable and faithfully reproduce key aspects of latent HCMV 
infection
312,318,319
. These cells allow for an HCMV infectivity rate of up to 11% at high MOI, 
include the ability to maintain viral genome carriage in the relative absence of lytic IE gene 
expression, and also permit the expression of latency-associated genes, such as LUNA, 
following infection with clinical isolates of HCMV
312
. In addition, unlike THP-1 cells, which 
can also support the above aspects of latency, Kasumi-3 cells have the noted ability to support 




To confirm that Kasumi-3 cells supported latent infection and productive replication in this 
investigation, cells were infected using the low-passage strain TB40-BAC4, which expressed 
the lytic MIE gene IE2 fused to red fluorescent protein (RFP). After 3 days post-infection, no 
detectable IE2 protein was present, however these cells were still able to reactivate upon 
differentiation (Figure 5.1). Additionally, cells that were differentiated prior to infection 
exhibited a permissive phenotype for lytic infection (Figure 5.1). These results are consistent 





















































































Figure 5.1. Initiation of lytic gene expression is differentiation-dependent in     
Kasumi-3 cells 
Undifferentiated Kasumi-3 cells were infected at MOI = 3 with recombinant TB40-BAC4 
strain ectopically expressing RFP fused to IE2 and incubated for 3 days prior to being 
analysed (latency). Following the 3-day period of latency establishment, the same samples 
were treated with phorbol 12-myristate 13-acetate for 48h to promote differentiation 
before analysis (reactivation). Additionally, separate cultures of Kasumi-3 cells were      
pre-treated with phorbol 12-myristate 13-acetate for 48 h prior to being infected (lytic). 
Cells were analysed directly by immunofluorescence, presented graphically (A) and 
enumerated in (B). Data shown represent averages of triplicate samples of six fields of 



































5.2.2. Transient expression of LUNA correlates with an increase in the 
activity of latency-associated viral gene promoters 
 
To examine the impact of LUNA on viral transcriptional activation, transient co-transfection 
assays were performed to express the protein in isolation and subsequently observe its effects 
on the levels of activity of latency-associated viral gene promoters derived from UL144 and 
LUNA. Having shown that the Kasumi-3 cell line supports latent HCMV infection in vitro, 
these cells were subsequently used as a model system for homologous expression so as to 
provide a cellular context that was as closely related to latency establishment as possible. 
 
Consistent with the changes in virus gene expression observed earlier at the mRNA level, the 
expression of wild-type LUNA routinely resulted in increased levels of transcriptional 
activation from the UL144 promoter and LUNA promoter (compared to empty transfected 

















































































Figure 5.2. Transient overexpression of LUNA activates the promoters of          
latency-associated viral genes 
The CD34
+
 myeloblastic cell line Kasumi-3 was transiently co-transfected with luciferase 
reporter plasmids (pGL3) under the control of latency-associated viral gene promoters and 
effector expression vectors (pCMV-Tag2b) containing FLAG-tagged wild type LUNA 
(WT). Cells were harvested 48 hours post transfection, then assayed for luciferase 
expression. Results are given as background-subtracted relative light units. Data presented 
are pooled from 3 biological replicates, with bars representing the averages of duplicate 
measurements, and standard deviations shown. Student’s t test was used to determine the 
significance of differences in promoter activity between Empty and LUNA WT 
transfections. 
UL144 promoter reporter 














































5.2.1. Knockdown of major ND10 component PML in combination with 
direct expression of LUNA exerts a positive effect on the 
activation of UL144 promoter, but not LUNA promoter 
 
The ability of LUNA to augment the activation of latency-associated viral gene promoters, as 
shown above, may be linked to the disruption of ND10 structures and the delocalisation of 
host restriction factors from viral genomes. This is plausible given that it has already been 
shown that ND10 are disrupted following the isolated expression of LUNA in Kasumi-3 cells. 
To determine whether ND10 are directly involved in affecting the ability of LUNA to 
augment the activity of latency-associated viral gene promoters, the levels of LUNA-mediated 
promoter activation were assayed in the absence of PML using RNA interference knockdown. 
THP-1 cells recombineered to express shRNA to PML were used as the expression system 
since they have also been shown to act as a tractable model of latent infection in previous 
studies.  
 
Despite no statistical significance when the data are interrogated, a trend is nonetheless 
observed whereby in the presence of cellular ND10 (siC), the LUNA promoter is activated 
following co-transfection of the LUNA gene, but such a trend is not observed in cells that 
have already had ND10 knocked down by siPML (Figure 5.3A). This supports the notion that 
LUNA functions to activate gene expression, insofar as the LUNA promoter is concerned, by 
disrupting ND10. Notably, while it is unclear why a greater magnitude of responsiveness to 
LUNA expression was seen in siC cells compared to siPML, one may posit that the different 
properties between the two cell types may have impacted on the final outcome of the assay. 
The UL144 promoter is different in that, again although not statistically significant, a trend is 
observed showing that this promoter is activated by LUNA co-transfection in cells with PML 
bodies; however in cells devoid of ND10 that activation is more substantial and is statistically 
significant (Figure 5.3B). Thus, at least for the UL144 promoter, LUNA appears to act in a 
PML independent fashion. Regardless, it is clear that further repeats of this experiment are 
necessary to determine if the effects of LUNA are drawn primarily from their ability to disrupt 
PML since one would expect to see a significant difference between LUNA transfections 
compared to empty transfection controls in cells where ND10 are intact, but not where ND10 































































Figure 5.3. In the context of PML protein depletion, only the UL144 promoter, but 
not the LUNA promoter, is responsive to LUNA protein expression  
THP-1 cells stably expressing either functionally inactive shRNA (siC) or shRNA to PML 
(siPML) were transient co-transfected with with luciferase reporter plasmids (pGL3) 
under the control of latency-associated viral gene promoters and effector expression 
vectors (pCMV-Tag2b) containing FLAG-tagged wild type LUNA (WT). Cells were 
harvested 48 hours post transfection, then assayed for luciferase expression. Results are 
given as background-subtracted relative light units. Data presented are pooled from three 
biological replicates, with bars representing the averages of duplicate measurements, and 
standard deviations shown. Statistical analysis was by one-way ANOVA (LUNA reporter:    
F = 1.44, d.f. = 11, P > 0.01; UL144 reporter: F = 15.70, d.f. = 11, P < 0.01), using a post-hoc 
Tukey's multiple comparison test. For samples containing LUNA reporter, no statistical 
significance was observed between any of the groups. For samples containing UL144 reporter, 
only results generated from transfection of LUNA expression vectors into siPML cells were 
statistically significant compared to all other groups (*). 
 
B. 
LUNA promoter reporter 











































5.2.2. LUNA and the host transcription factor GATA-2 cooperate to 
exert an additive effect on the activation of latency-associated 
viral gene promoters  
 
Previous reports have shown that the LUNA and UL144 promoters possess binding sites for 
the host transcription factor GATA-2, which has been implicated in promoting the expression 
of these genes during latency
215
. To determine whether the viral LUNA protein itself may aid    
GATA-2-mediated transactivation of latency-associated viral gene promoters, both LUNA and 
GATA-2 were introduced into the same reporter expression system developed in              
Kasumi-3 cells to measure their possible combined effect on latency-associated promoter 
activation.  
 
As before, the activities of the LUNA promoter and UL144 promoter were upregulated in 
response to the sole expression of wild-type LUNA (Figure 5.4). This effect was also similarly 
observed in the case of GATA-2, which is consistent with previous published data 
demonstrating that both promotors – which had been derived from the low-passage strain 
Merlin – are responsive to GATA-2 (Figure 5.4). Notably, however, the co-expression of both 
LUNA and GATA-2 resulted in a cooperative, additive effect on the activation of both 













































































Figure 5.4. Co-transfection of LUNA and GATA-2 exerts a combined, additive effect 
on the activity of latency-associated viral gene promoters 
Kaasumi-3 cells were co-transfected for 48h with luciferase reporter plasmids (pGL3) 
under the control of the LUNA promoter (A) or UL144 promoter (B), along with effector 
vectors pCMV-Tag1A containing empty (Tag1A) or Triple-Flag-tagged wild type LUNA 
(LUNA); and pEF3.1 containing empty (pEF) or wild type GATA-2 (GATA-2) cDNA. 
Results are presented as background-subtracted relative light units (RLU). Data were 
pooled from 3 biological replicates, with bars representing the averages of duplicate 
measurements, and standard deviations shown. Student’s t test was used to determine the 
significance of differences in promoter activity between LUNA + GATA-2 against 
LUNA only and GATA-2 only transfections. 
B. UL144 promoter reporter 


















































5.2.3. LUNA exhibits a physical interaction with GATA-2 in vitro 
 
The viral latent gene product LUNA and host transcription factor GATA-2 appear to work 
cooperatively to facilitate the transcriptional activation of latency-associated viral genes, 
insofar as LUNA and UL144 are concerned. To this end, a physical protein-protein interaction 
might exist between LUNA and GATA-2, which might be important to enable their combined 
functionality.  
 
Following pull-down of FLAG-tagged LUNA with anti-FLAG antibody, GATA-2 was 
detected using anti-GATA-2 antibody by Western blotting of lysates from HEK293T cells 
simultaneously co-transfected with FLAG-LUNA and GATA-2 expression vectors 
(Figure 5.5). This indicates that a physical interaction exists between the two proteins. 
Notably, the band for GATA-2 was seen at approximately ~110kDa, indicating that the 






























Figure 5.5. Viral LUNA protein interacts with host transcription factor GATA-2          
in vitro 
Triple-FLAG-tagged LUNA (LUNA) was immunoprecipitated with anti-FLAG rabbit IgG 
antibodies from HEK293T cells co-transfected with expression vectors containing GATA-2 
and LUNA. Cell lysates before immunoprecipitation (Input) and immunoprecipitates (IP) 
were analysed by SDS-PAGE and immunoblotting (IB) with indicated antibodies. Arrow 
indicates the position of GATA-2. To further substantiate this finding, a reverse-pulldown 
was carried out, but was unsuccessful. 











The results of this investigation demonstrate that LUNA is able to regulate the expression of 
latency-associated genes at the transcriptional level, specifically, by augmenting the activity of 
viral gene promoters which are otherwise known to be active during latency (Figures 5.2 and 
5.3). Thus, consistent with the findings observed earlier in Chapter 4, these data support a 
potential mechanistic pathway by which LUNA may exert control over latency-associated 
viral gene expression.  
 
The depletion of PML appears to impact on the ability of LUNA to activate its own promoter, 
consistent with the view that LUNA functions by disrupting ND10 bodies during latent 
infection; however, it does appear that LUNA may promote gene expression by other 
mechanisms besides ND10 disruption, as evidenced by the responsiveness of the 
UL144 promoter to LUNA expression when PML was already absent. Nevertheless, with the 
exception of results pertaining to the UL144 promoter in the absence of PML, the data 
obtained are non-significant, requiring additional repeats before any firm conclusions may be 
drawn outright. 
 
Notably, the observation that LUNA expression correlates with the activity of its own 
promoter, indicates that LUNA is associated with the positive autoregulation of itself. If 
LUNA is responsible for stabilising its own expression during latency, as well as presumably 
that of other latency-associated gene transcripts (e.g. UL138), this raises the question as to 
how LUNA may come to be expressed initially upon latent infection. One possible explanation 
is that other factors may be involved in activating LUNA gene expression, which may then 
result in subsequent formation of a positive-feedback loop affecting other promoters. 
Consistent with this, binding of the host transcription factor GATA-2 to the LUNA promoter 
has previously been reported, and here, has been shown to increase LUNA promoter activity 
in transfection assays
215
. Interestingly, the combined presence of LUNA and GATA-2 also 
yields an additive effect on transcriptional activation (Figure 5.4). In support of their ability to 
cooperate together, both LUNA and GATA-2 appear to demonstrate a physical interaction 





6. Evaluating the impact of a LUNA intrinsic 
deSUMOylase activity upon the regulation of viral gene 




Recent protein sequence analysis of LUNA, performed in collaboration with Dr Matthew 
Reeves (UCL), has revealed that the protein possesses short amino acid homology to cellular 
enzymes known to be involved in the ubiquitin-like modification of cellular proteins (Poole et 
al. Under review). In particular, this homology resembles the active sites of known 
isopeptidases capable of deSUMOylating protein targets. Because SUMOylation of PML is 
well documented to be important for ND10 integrity, LUNA-mediated deSUMOylation of 
PML might explain how it is able to disrupt ND10 following its expression in vitro. 
Consequently, on this basis alone, LUNA would be predicted to be able to contribute towards 
the regulation of HCMV gene expression during latency. Here, evidence will be presented to 
demonstrate the extent to which the function of LUNA, as characterised so far, is dependent 




















6.2.1. LUNA encodes a candidate enzymatic motif that exhibits an 
isopeptidase activity 
 
Bioinformatics analysis of LUNA was first performed using InterPro-scan (InterPro;     
EMBL-EBI) to identify any homology with known protein families. This revealed minimal 
sequence homology with host cellular proteins, but nonetheless reported a possible identity 
with ubiquitin-like modifying enzymes. Because ubiquitin-like modifiers typically possess a 
catalytic active site within their C-terminal domain, subsequent analysis of LUNA focussed on 
amino acids 70-133. Using the above sequence as a query, BLAST (NCBI, Bethesda, MD) 
searches of public databases showed similarity between LUNA and the C-terminal catalytic 
domain of the human Senp family. This family belongs to a group of so-called SUMO-specific 
isopeptidases that catalyse the removal of SUMO conjugates from protein substrates, 
employing a common hydrolytic mechanism that makes use of a conserved active cysteine 
residue
320
. In support of its classification as a potential isopeptidase, further sequence analysis 
of LUNA uncovered a candidate conserved enzymatic motif in its C-terminal domain that 
featured a critical cysteine residue flanked by glycine and aspartic acid (Figure 6.1). The motif 
itself shares homology with the yeast Ulp1 (ubiquitin-like protein 1) cysteinyl protease found 

















MTSVRAPLLP LRRLCPVRIS AGDSP AWVSE SSSPLASSKP  
ANM ASDRGVG VGVEERSSSS SSSSSSSSSS VGGNPGDCGR  
NSETAPRMTL LRGKRP ARSC TWGRLILSGL PGVRVQNPRR  






Figure 6.1. Identification of the putative catalytic site in the LUNA C-terminal 
domain 
Bioinformatics analysis of the 133-amino-acid serine-rich LUNA protein revealed 
sequence similarity in its C-terminal domain with that of a group of SUMO-specific 
isopeptidases found in the humans. The location of the candidate conserved enzymatic 
motif is outlined by the red box, with the putative active cysteine residue marked by the 
red asterix. 
91 
In view of the predicted homology with ubiquitin-like modifying enzymes, an investigation 
was performed to evaluate whether LUNA was in possession of an isopeptidase activity, 
specifically concerning the removal of SUMO moieties from proteins (i.e. deSUMOylation). 
Using an enzymatic assay, levels of deSUMOylase activity exhibited by wild type LUNA 
were measured against that of a known cellular control, SENP2/SuPr-1 (SENP2CD)
322
. 
Importantly, the analysis was extended to include the use of a LUNA mutant (LUNAg233c), 
which had had the putative active cysteine changed to an inactive serine, in order to 
demonstrate that any catalytic activity associated with LUNA was faithful to its candidate 
active site (Figure 6.2A). 
 
Purified recombinant LUNA protein showed comparable levels of activity to the control 
SENP2CD protein, suggesting that it functioned as a deSUMOylase enzyme (Figure 6.2B)
317
. 
Furthermore, the finding that equivalent amounts of mutant LUNAg23c showed no activity in 
the same assay, indicated that the active site encoded by LUNA was functionally responsible 













































































Figure 6.2. LUNA exhibits a novel deSUMOylase activity that is dependent on a 
putative active site featuring a catalytic cysteine residue in its C-terminal domain 
(Figure courtesy of Matthew Reeves) 
A. The amino acid and corresponding nucleotide sequence for wild-type LUNA based on 
current sequence of HCMV strain Merlin. Site directed mutagenesis of nucleotide 233 
was performed to convert it from a G → C, thereby changing the putative catalytic 
cysteine residue to an inactive serine and giving rise to the so-called ‘g233c’ LUNA 
mutant. B. The capacity of wild-type LUNA and the catalytically inactive g233c mutant 
to cleave SUMO substrate motifs was measured by fluorescence activity of a known 
substrate, SUMO-3, in a reporter assay.  SUMO-3 was incubated with a known 
deSUMOylase Senp-2 (positive control), or 2-fold dilutions of wild-type LUNA or 




6.2.2. Disruption of ND10 by LUNA is dependent on its novel encoded 
deSUMOylase activity  
  
Earlier in Section 1.1.1., transfection analyses conducted in Kasumi-3 cells showed that a 
greater proportion of cells were devoid of ND10 structures following the direct expression of 
LUNA compared to empty vector controls. Consequently, this suggested that LUNA had a 
role in mediating their disruption.  
 
To determine whether the disruption of ND10 was linked to the ability of LUNA to function 
as deSUMOylase, use of the LUNAg233c catalytic mutant was also included in this analysis. 
Interestingly, a reverse trend was observed, whereby cells transfected with LUNAg233c showed 
hardly any evidence of ND10 disruption, with levels of intact ND10 comparable to that seen 
in empty vector controls, but not compared to transfection of LUNA (Figure 6.3). This finding 
indicates that LUNA-mediated disruption of ND10 is dependent on its ability to function as a 
deSUMOylase, which further supports the notion that the integrity of ND10 is susceptible to 
deSUMOylation. Furthermore, consistent with previous images showing WT LUNA 
expression in Kasumi-3 cells in Figure 3.5, LUNAg233c was largely localised to the nucleus. 
That said, I am aware that expression of the g233c mutant-FLAG tag LUNA was not assayed 
for differences in stability (e.g. arising from possible gross misfolding) and this will need to be 













































































Figure 6.3. Myeloid cells transfected with LUNAg233c fail to show disrupted ND10 
The early myeloid cell line, Kasumi-3, was transiently transfected with expression 
plasmids encoding wild type FLAG-LUNA (as shown earlier in Figure 4.0) or mutant 
FLAG-g233c fusion protein. (A) 48 hours post transfection, cells were cytospinned and 
stained for LUNA (green), PML (red) or nuclei (blue) (magnification; × 100). Yellow 
arrows point to a successfully infected cell exhibiting disruption of ND10 by PML 
staining. White arrows point to uninfected cells containing intact ND10. (B) The number 
of transfected ND10 positive or negative cells were enumerated using ImageJ software. 
Bars represent averages of 5 fields of view of 100 cells, each showing standard deviation. 
 
























































































6.2.1. Regulation of HCMV gene expression during latent infection is 
affected by the novel deSUMOylase activity encoded by LUNA  
  
The results presented in Chapter 4 show that LUNA is required for efficient viral gene 
expression during latent HCMV infection of primary myeloid cells. Additionally, they 
revealed that the expression of LUNA coincided with the gain and loss of activatory and 
repressive histone modifications, respectively, over the promoters of latency-associated genes. 
Combined, the data support the view that LUNA is involved in regulating viral gene 
expression during latency; though, it remains unclear as to whether the deSUMOylase activity 
of LUNA is responsible for mediating the phenotypic changes in gene expression observed. In 
order to interrogate this further, the same analyses – which had been performed in latency 
infected CD14
+
 monocytes – were expanded to include the use of a mutant virus (g233c), 
which carried the same defect in recombinant LUNA that eliminated the catalytic cysteine and 
was previously shown to be important for ND10 disruption in transfection analyses. This 
mutant did not appear to be affected in its ability to undergo lytic replication (Figure 6.4).  
 
As with the original findings obtained using the LUNA deletion virus, the g233c virus 
displayed a substantial defect in its ability to induce the expression of both UL138 and 
IE genes during latent viral infection (Figure 6.5). Further still, latent infection with the 
g233c virus produced similar changes in histone modification patterns over the promoters of 
latency-associated genes, UL144 and LUNA (Figure 6.6). Together, this suggested that LUNA 
mediated its regulatory effects on virus gene expression during latency through its ability to 





























































Figure 6.4. Growth of the LUNA g233c mutant virus showed no defect 
HFFs were infected at an MOI of 0.01 with wild type Merlin (WT) or LUNA g233c 
mutant (g233c) virus and the growth measured over 10 days. Supernatants were titred for 





















































































Figure 6.5. The putative deSUMOylase activity of LUNA is required for efficient     
latency-associated viral gene expression in latently infected CD14
+
 monocytes 




cells per well) latently infected with 
revertant (Rev) and LUNA g233c mutant (g233c) viruses at MOI = 5 were analysed for 
IE1 gene expression by RT-qPCR 3 days post infection. All samples were normalised to 
GAPDH. Data presented are pooled from 3 biological replicates, with bars representing 
the averages of duplicate measurements, and standard deviations shown. Student’s t test 
was used to determine the significance of differences in gene expression between Rev 














































































































Figure 6.6. LUNA-mediated changes in histone modification patterns during latency 
are linked to its deSUMOylase activity 
Chromatin immunoprecipitation assays with anti-histone H3 trimethylated at lysine 4  





 cells latently infected with revertant (Rev) or LUNA g233c (g233c) virus 
at MOI = 4. Samples were amplified using primers targeting known regions in the LUNA 
promoter and UL144 promoter and expressed as a logarithmic function over the Input. 
H3K4me3 enrichment is represented in A. TLR4 was used as a positive control candidate 
for H3K4me3 enrichment. H3K9me3 enrichment is represented in B. ZNF180 was used a 
positive control candidate for H3K9me3 enrichment. Bars represent averages of triplicate 
analyses from two independent experiments, with standard deviation shown. Student’s 
t test was used to determine the significance of the differences in histone enrichment 
between infections with Rev and g233c viruses. Points with no error bars represent 
averages of triplicate measurements from a single experiment. 
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B. H3K9me3 enrichment (repressive) 
p<0.05 p=NS 
99 
6.2.1. Activation of latency-associated viral gene promoters is 
associated with the deSUMOylase activity of LUNA 
  
Previously in Chapter 5, the expression of LUNA protein in Kasumi-3 cells was shown to 
transactivate latency-associated viral gene promoters derived from HCMV UL144 and LUNA. 
While a similar effect was also observed using THP-1 cells, where PML protein had been 
depleted by shRNAs, only the UL144 promoter, but not the LUNA promoter was found to be 
responsive to LUNA expression. Together, this suggested that LUNA was able to regulate the 
activity of latency-associated viral gene promoters, likely, by mediating the disruption of 
ND10 structures; however, in some cases, LUNA may have been able to exert its effect via an 
alternative mechanism which was independent of ND10 disruption. In order to reinforce the 
view that LUNA-mediated promoter activation was linked to its ability to disrupt 
ND10 structures, the same reporter assays were performed in transfected cells as detailed but 
using the LUNAg233c catalytically dead mutant.  
 
Consistent with the notion that the gene activatory function of LUNA was dependent on its 
ability to act as a deSUMOylase, co-transfection of the LUNAg233c mutant in Kasumi-3 cells 
failed to produce any effect on the LUNA promoter (Figure 6.7). However, expression of 
LUNAg233c was associated with an increase in promoter activity for the UL144 promoter 
(Figure 6.7). Although this effect did not reach the same level of magnitude as that obtained 
by co-transfection of wild type LUNA, that the UL144 promoter was responsive to the 
expression of the LUNAg233c does indicate that LUNA may also partially function in a         
deSUMOylation-independent manner, insofar as the UL144 promoter is concerned 
(Figure 6.7). This specific trend was consistent in transfection assays performed with both 
LUNAg233c and GATA-2, whereby the only additive effect on promoter activity was observed 
for the UL144 promoter, but not the LUNA promoter (Figure 6.8). 
 
Additional transient co-transfection experiments with the LUNAg233c mutant were also 
performed using control THP-1 cells (siC) and THP-1 cells with PML knocked down by 
shRNA technology (siPML). Despite a lack of statistical significance, a trend was observed 
indicating that co-transfection of LUNAg233c did not yield any change in activity of the 
LUNA promoter in either siC or siPML cells, unlike co-transfection of wild-type LUNA, 
which produced a small positive upregulatory effect. This finding suggests that LUNA can 
activate its own promoter and that this is dependent on its deSUMOylase activity in cells with 
ND10. By contrast, interrogation of the activity of the UL144 promoter gave a different set of 
100 
results, this time with positive upregulation being reported in both PML-positive and        
PML-negative cells following co-transfection of LUNAg233c, which was comparable to that of 
wild-type LUNA. This finding suggests that LUNA is also able to upregulate the activity of 
the UL144 promoter through a mechanism that does not depend on its deSUMOylase activity 
and hence the need for disrupted ND10. To account for the differences (compared to the 
LUNA promoter), in magnitude in the response of the UL144 promoter to LUNAg233c in 
siPML cells compared to siC cells it is possible that the absence of ND10 may promote the 



















































































Figure 6.7. The LUNA g233c mutant protein does not exert an effect on the HCMV 
LUNA promoter, but yields a moderate increase in activity of the UL144 promoter 
The CD34
+
 myeloblastic cell line Kasumi-3 was transiently co-transfected with 
luciferase reporter plasmids (pGL3) under the control of latency-associated viral gene 
promoters and effector expression vectors (pCMV-Tag1A) containing triple           
FLAG-tagged LUNAg233c (g233c). Cells were harvested 48 h post transfection, then 
assayed for luciferase expression. Results are given as background-subtracted relative 
light units (RLU). Error bars denote the standard error of samples measured over three 














































































































Figure 6.8. Co-transfection of LUNAg233c mutant and GATA-2 yields a combined, 
additive effect only on the HCMV UL144 promoter, but not the LUNA promoter 
Kaasumi-3 cells were co-transfected for 48 h with luciferase reporter plasmids (pGL3) 
under the control of the LUNA promoter (A) or UL144 promoter (B), along with effector 
vectors pCMV-Tag1A containing empty (Tag1A) or Triple-Flag-tagged LUNAg233c 
(g233c); and pEF3.1 containing empty (pEF) or wild type GATA-2 (GATA-2) cDNA. 
Results are given as relative light units. Samples were background-substracted. Data 
presented are pooled from 3 biological replicates, with bars representing the averages of 
duplicate measurements, and standard deviations shown. Student’s t test was used to 
determine the significance of differences in promoter activity between g233c + GATA-2 
against g233c only and GATA-2 only and LUNA + GATA-2 transfections. 
 
 























































































































Figure 6.9. In the context of PML protein depletion, only the UL144 promoter, but 
not the LUNA promoter, is responsive to LUNA g233c mutant expression 
THP-1 cells stably expressing either functionally inactive shRNA (siC) or shRNA to PML 
(siPML) were transient co-transfected with luciferase reporter plasmids (pGL3) under the 
control of latency-associated viral gene promoters and effector expression vectors (pCMV-
Tag1A) containing FLAG-tagged LUNAg233c (g233c). Cells were harvested 48 hours post 
transfection, then assayed for luciferase expression. Results are given as background-
subtracted relative light units. Data presented are pooled from 3 biological replicates, with 
bars representing the averages of duplicate measurements, and standard deviations shown. 
Statistical analysis was by one-way ANOVA (LUNA reporter: F = 1.44, d.f. = 11, P > 0.01; 
UL144 reporter: F = 15.70, d.f. = 11, P < 0.01), using a post-hoc Tukey's multiple 
comparison test. For samples containing LUNA reporter, no statistical significance was 
observed between any of the groups. For samples containing UL144 reporter, only results 
generated from transfection of g233c expression vectors into siPML cells were statistically 
significant compared to all other groups, except LUNA WT. 
 
LUNA promoter reporter 






















































The results presented in this chapter build upon the previous functional characterisation of 
LUNA by demonstrating that the protein possesses an isopeptidase activity that allows it to act 
as a deSUMOylase (Figures 6.1 and 6.2). This activity appears to be critical for the ability of 
LUNA to disrupt ND10 structures (Figure 6.3). Furthermore, it is also important for regulating 
viral gene expression during HCMV latency, as transcription and epigenetic analyses of        
latency-associated viral gene promoters using the g233c mutant virus provided similar results 
as a LUNA deficient mutant (Figures 6.5 and 6.6). However, at the level of transcriptional 
activation, the deSUMOylase activity of LUNA appears to be crucial for transactivation of the 
LUNA promoter, but not the UL144 promoter (Figures 6.7 and 6.8). This indicates that for 
these promoters in particular, the regulation of the LUNA promoter requires ND10 disruption, 
whereas for the UL144 promoter, it is possible that LUNA may facilitate regulation via an 
alternative mechanism that is not deSUMOylase-dependent. Together, these data strengthen 
the notion that LUNA mediates its regulatory effects on some latency-associated viral gene 
expression during latent infection by promoting the disruption of ND10 bodies, but may also 
facilitate similar regulation through another as yet unidentified means. When similar assays 
were performed using THP-1 cells, expression of the LUNAg233c mutant also gave a similar 
trend of result as Figures 6.7 and 6.8, with the LUNA promoter showing on upregulation of 
activity, but activation seen for the UL144 promoter, which was statistically significantly in 
the absence of PML. This also suggests that the functionality of LUNA may depend on its 
ability to disrupt ND10, but also by some other deSUMOylase-independent means, whose 
effect varies according to the target promoter. The greater magnitude of upregulation seen in 
THP-1 cells by transfection of LUNAg233c on the UL144 promoter, compared to that seen in 
Kasumi-3 cells, may be accounted for by core differences in properties between the two cell 
types  (i.e. myelomonocytic vs CD34
+
 phenotypic, respectively). Overall, whilst the above 
data warrants further investigation into mechanism by which LUNA may mediate          
latency-associated viral gene expression in the context of ND10 disruption as well as 
inhibition of deSUMOylation, it will also require further analysis using a greater range of 






7. Investigating human silencing hub (HUSH) complex and 




The findings reported throughout this investigation support the role of LUNA in regulating 
HCMV gene expression during latency, likely, mediated by its novel deSUMOylase activity    
that allows it target cellular ND10 structures for disruption. Given that cellular ND10 are but   
one example of factors which contribute towards the intrinsic restriction of herpesviruses, I     
also reasoned that it was also of particular relevance to consider the impact of other factors 
that may also be involved in inhibiting HCMV lytic gene expression, specifically, in regards 
to latent infection. 
 
Recently, in a study performed on the regulation of transgene silencing of retroviruses, 
Tchasovnikarova et al. identified a novel chromatin-associated complex that spreads 
repressive histone modifications onto newly inserted retroelements
323
. This complex, termed 
the human silencing hub (HUSH), is composed of three proteins, the chromodomain protein 
M-phase phosphoprotein 8 (MPP8), the transgenic activation repressor (TASOR) and 
Periphilin 1 (PPHLN1)
324–326
. Through its baseline interaction with heterochromatin, HUSH 
directly recruits the chromatin modifier SET domain, bifurcated 1 (SETDB1), to mediate the 
deposition of H3K9me3 over new genomic insertions
323,327
. Such spreading of 
heterochromatin from adjacent sequences provides a mechanistic explanation for the related 
phenomenon observed in Drosophila known as positional effect variegation
328
. Recently, 
KRAB-associated protein 1 (KAP1), a well-known host co-repressor involved in regulating 
multiple aspects of mammalian homeostasis, was reported to play a role in HCMV latency by 
directing the recruitment of SETDB1 and HP1 to the viral genome, resulting in the deposition 
of H3K9me3 marks and transcriptional silencing
244
. However, whether HUSH may also 
contribute towards SETDB1-mediated silencing of viral genomes remains to be determined. 
Consequently, the aim of this investigation was to evaluate the role of the HUSH complex in 







7.2.1. Knockdown of the HUSH complex and SETDB1 can be 
performed in vitro using shRNA-expressing vectors 
 
Prior to assessing the role of the HUSH complex, it was first necessary to develop a method of 
eliminating its function in vitro. To achieve this, shRNA-mediated knockdown of components 
of HUSH, and the key HUSH-associated protein, SETDB1, was performed using lentiviral 
vectors that had been developed by Richard Timms and Daniel Greaves (Lehner group; 
University of Cambridge). Efficient knockdown of HUSH components, TASOR, Periphilin 1 
and MPP8, in addition to SETDB-1 in THP-1 cells was observed following transduction of the 


































Figure 7.1. Transduction of shRNA targeting components of HUSH and SETDB-1 
results in their respective knockdown in THP-1 cells 
THP-1 cells were transduced with lentiviruses expressing shRNA against the following 
components of HUSH, TASOR (shTASOR), Periphilin 1 (PHL) and MPP8 (shMPP8) as 
well as SETDB-1 (shSETDB-1). Vectors expressing scrambled shRNA was used as a 
control (CTRL). After 48 hours post-transduction, cells were harvested for western 






7.2.1. The HUSH complex is not required for the maintenance of      
HCMV latency  
 
To determine whether the HUSH complex was essential for HCMV latency, CD34
+
 cells were 
first latently infected with an IE2-YFP tagged virus. Next, these cells were targeted by lentiviral 
vectors expressing shRNA targeting HUSH components and levels of reactivating lytic IE2 
gene expression were quantified by immunofluorescent staining. The rationale for this 
experiment is supported by the fact that after HUSH-mediated repression is established, there is 
an ongoing requirement for the complex to maintain the state of epigenetic repression
323
. As 
such, it has been proposed other opposing mechanisms may be present that seek to reverse the 
heterochromatic state brought about through HUSH, such as a competing active H3K9me3 
demethylase activity
329
.    
 
Following transduction of shRNA targeting TASOR (shTAS) and SETDB1 (shSET), 
compared to shRNA controls (shControl), the numbers of IE2-YFP expressing foci showed a 
marginal increase (Figure 7.2). This initially suggested that components of the HUSH 
complex could play a minor role on the suppression of lytic gene expression during latency. 
However, it should be bone in mind that in this analysis, confirmation of the levels of 
expression of SET and TASOR were not analysed due to a lack of available CD34
+
 cell 
samples and equivalent efficiency of TASOR and SET knockdown was assumed on the basis 




















































































Figure 7.2. Transduction of shRNA targeting HUSH components has little effect on 
reactivation of latently infected CD34
+
 cells  
Primary CD34
+
 cells were latently infected with TB40-BAC4 IE2-YFP tagged virus at 
MOI = 5 and incubated for 3 days to establish latency. Cells were then transduced with 
lentivirus expressing shRNA targeting TASOR (shTAS), SETDB1 (shSET) or 
scrambled shRNA (shCTRL), and monitored for YFP-expressing foci. The relative 
number of YFP-expressing cells were enumerated using ImageJ software. Values 
represent averages of 5 fields of view of 100 cells, each with SD error bars. Counts were 
made 15 days post-infection. Student’s t test was used to determine the significance of 












Figure 9. In the context of PML protein depletion, only the UL144 promoter, but 
not the        LUNA promoter, is responsive to LUNA g233c mutant expression 
THP-1 cells stably expressing either functionally inactive shRNA (siC) or shRNA to 
PML (siPML) were transient co-transfected with luciferase reporter plasmids (pGL3) 
under the control of latency-associated viral gene promoters and effector expression 




7.2.2. Components of the HUSH complex are not associated with 
epigenetic regulation during latency 
 
To interrogate the effect of HUSH-mediated regulation on HCMV latency further, I performed 
ChiP assays on the same latently infected CD34
+
 cells which were subjected to HUSH 
knockdown in order to analyse levels of histone modification surrounding the MIEP.  
 
No discernible trend was observed consistent with these factors affecting chromatin marks 
around the MIEP in latently infected cells, suggesting that HUSH is not critical in regulating 
HCMV latency (Figure 7.3). Notably, levels of H3K4me3 enrichment, a marker of 
transcriptional activation, showed no significant difference between the samples relative to 
control shRNA. Although repressive H3K9me3 levels were lower in cells transduced with 
shSET than shTASOR, relative to control, no clear result may be drawn from this owing to a 














































































Figure 7.3. Transduction of shRNA targeting HUSH components and SETDB1 yields 




 cells previously infected with TB40-BAC4 IE2-YFP tagged virus were harvested 
after 10 days post-transduction of shRNA for ChIP analysis. Assays were performed using                   
anti-H3K4me3, anti-H3K9me3 or isotype control (IgG) antibodies. Samples were 
amplified using primers targeting known regions in the MIEP and expressed as a 
logarithmic function over the Input. H3K4me3 enrichment is shown in A. H3K9me3 
enrichment is shown in B. Bars represent averages of triplicate analyses from two 
independent experiments, with standard deviation shown. Student’s t test was used to 
determine the significance of the differences in histone enrichment between transductions 
with shC against shSET and shTAS. Points with no error bars represent averages of 
triplicate measurements from a single experiment. 
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7.2.3. Knockdown of HUSH yields no effect on the activity of the MIEP 
in early myeloid cells 
 
Presently, it is understood that only newly inserted retroelements (transgenes) may be 
subjected to HUSH-mediated silencing. To that end, it may be the case that HUSH is not 
involved in the regulation of HCMV latency, given that such viral episomes do not undergo 
integration into the host genome. Indeed, this scenario is consistent with the data presented so 
far in Chapter 7. Nonetheless, to explore this further in the context of HUSH complex 
function, an experiment was performed to compare levels of activity of MIEP-reporter in 
THP-1 cells between those which had either had the reporter integrated into the host genome 
or introduced by transient transfection. 
 
Following transduction of shRNA targeting HUSH or SETDB1, THP-1 cells containing the 
integrated reporter showed a significantly raised level of MIEP activity, relative to shRNA 
controls (Figure7.4A). However, in contrast to cells where the MIEP-reporter had been 
inserted as non-integrated plasmid, no significant increase in activity was observed compared 
to shRNA controls, as indeed, they were found to show a counterintuitive repression      
(Figure 7.4B). Together, these results indicate that non-integrated viral episomes are not likely 









































































Figure 7.4. Knockdown of HUSH in THP-1 cells containing stably integrated 
reporters show increased levels of MIEP activity, as measured by luciferase 
expression, but this effect is not observed in cells containing plasmid reporters that 
have been introduced by transient transfection 
Luciferase assays were performed to measure the effect of HUSH knockdown on the 
activity of the HCMV MIEP in THP-1 cells. MIEP luciferase-based reporters were 
introduced into THP-1 cells either by genetic modification in order to generate cells 
containing stably integrated constructs (A) or by transient transfection using separate 
plasmid DNA (B). Knockdown of HUSH was performed using lentivirus transduction; 
shRNA targeting TASOR (shTAS), SETDB1 (shSET) or scrambled shRNA (shCTRL). 
Data presented are pooled from 3 biological replicates, with bars representing the 
averages of triplicate measurements, and standard deviations shown. Student’s t test was 
used to determine the significance of differences between shCTRL and shSET or shTAS. 
THP-1 cells with integrated MIEP reporter 















































Together, the findings of this investigation demonstrate that the HUSH complex is not likely 
to be involved in regulating HCMV latency with respect to suppressing lytic IE gene 
expression. Although immunoflorescence data demonstrates a weak trend implicating HUSH 
in the maintenance of latent infection, results from epigenetics analysis suggest that HUSH 
does not play a significant role overall. Indeed, this was further supported by the observation 
that viral MIEP-reporters which have been integrated into the host genome appear to be 
subjected to HUSH-mediated regulation (in that knock-down of HUSH components activated 
the MIEP), whereas transiently transfected MIEP reporters introduced as separate, circular 
plasmids – perhaps akin to viral episomes formed during infection – are not. Why knock-down 
of HUSH components leads to an apparent decrease in activity of transiently transfected 
MIEP-reporters remains unclear from the point of view of these analyses. One possible 
explanation is that the knock-down of HUSH components leads to an indirect effect that 
increases the expression of other cellular transcriptional repressors that can target vector-based 
MIEP-reporters and inhibit their overall level of luciferase expression. Overall, although 
HUSH serves as a potent host transcriptional repressor, the manner by which it functions does 
not appear to apply to HCMV with respect to normal conditions of infection. To this end, 
other known cellular regulators, such as early myeloid-associated transcription factors, may be 
directly responsible for mediating the formation of a repressed chromatin structure over the 


















The principle aims of this thesis were to evaluate the functional significance of a single 
HCMV latency-associated gene, LUNA, with respect to its regulatory effects on the latently 
infected cell. Much of the work is detailed across four investigative chapters, with a fifth 
chapter focussing on more exploratory research. The first chapter centres on the impact of 
latent HCMV infection on the host cell, in particular, examining whether cellular 
ND10 structures – known intrinsic inhibitors of herpesvirus replication – are disrupted as a 
result of latent infection and whether the viral latency-associated protein, LUNA, may be 
responsible for producing such a phenotype. The second chapter interrogates the putative 
regulatory function of LUNA (in lieu of its ability to promote the disruption of ND10) and 
assesses whether the expression of LUNA is associated with changes in virus gene 
transcription during latent infection. The third chapter examines the effect of LUNA on the 
activity of latency-associated viral gene promoters in order to suggest a possible mechanism 
by which LUNA may mediate transcriptional regulation. The fourth, penultimate chapter 
seeks to address whether the functionality of LUNA as a viral transcriptional regulator is 
provided by a novel isopeptidase activity (encoded within its C-terminal domain), which 
enables the protein to target ND10 for disruption. Finally, the fifth chapter enquires after the 
role of another set of host repressors in regulating HCMV latency through a distinct process 
known as transgene repression. 
 
In the first investigative chapter (Chapter 3), I showed that latent HCMV infection resulted in 
the disruption of ND10 structures, as revealed by a relative absence of PML-containing foci in 
latently infected early myeloid cells compared to uninfected controls. This novel finding 
indicates that viral-mediated disruption of ND10 occurs in both phases of the virus life cycle, 
where such disruption has only previously been observed in the context of lytic infection. 
Crucially, it now appears that the HCMV LUNA protein, a viral latency-associated factor may 
also be involved in disrupting ND10, specifically, when it is expressed under conditions that 
support latency. The mechanisms underlying this may differ from those described for the lytic 
genes, IE1 and pp71, which are also known to disrupt the functions of ND10. Broadly 
speaking, the disruption of ND10 during lytic infection fits with the notion of the virus 
overcoming the negative repressive effects instigated by a host intrinsic defence mechanism, 
such that productive infection of permissive cell types is not inhibited. By contrast, the 
apparent loss of these structures during latency is surprising, given that their presence is 
otherwise thought to contribute to the repression of viral genomes, an important criterion for 
115 
silencing IE gene expression and maintaining the virus in a latent state. Consequently, other 
regulatory mechanisms, beside the manifestation of ND10, are more likely to be implicated in 
controlling viral latency. Nevertheless, by allowing the virus to more efficiently express its 
genes, the disruption of ND10 during latent infection may serve a similar purpose as that for 
lytic infection. Indeed, it is well established that viral latency is dependent on the ability of 
HCMV to successfully undergo virus gene expression and any event that may help the virus 
to facilitate this should not be discounted. 
 
The next investigative chapter (Chapter 4) sought to determine whether LUNA played a 
putative role in regulating virus gene expression during latency. Using models of 
experimental latent infection based on primary myeloid cells, mutant Merlin viruses deficient 
in LUNA were analysed for their ability to express both latency-associated and lytic viral 
genes. In cells infected with LUNA knockout viruses, a clear lack of gene expression for the 
latent viral gene product UL138, and lytic IE1, was observed compared to those infected with 
wild type viruses. This finding indicates that LUNA is required for enabling efficient virus 
gene expression to occur during latency. Importantly, because UL138 is understood to be 
required for the maintenance of latent HCMV infection, the ability of LUNA to normalise 
UL138 expression during latency also provides evidence of its role in contributing towards 
this process. To account for the increased levels of MIE gene expression, it is conceivable that 
LUNA, by disrupting ND10, may be relieving the MIEP of a number of transcriptional 
repressors involved in targeting it for silencing. While ND10 disruption does not appear to be 
sufficient for viral reactivation from latency, likely because permissiveness for lytic infection 
remains intimately tied to the differentiation status of the host cell, there is ongoing evidence 
to suggest that LUNA is involved in promoting efficient viral reactivation
317
. In addition to 
the above findings, it was also shown that LUNA expression during latent infection coincided 
with the acquisition and loss of markers of transcriptional activation and repression, 
respectively, over the promoters of latency-associated viral genes. This observation highlights 
the impact of LUNA on molecular mechanisms governing latency-associated viral gene 
expression, which correlate with changes observed downstream at the mRNA level. Taken 
together, these results help to confirm that LUNA plays a role in regulating latency-associated 
virus gene expression during latency.  
 
To further characterise the function of LUNA during latency and build upon the investigations 
outlined in Chapter 4, the following series of experiments (Chapter 5) aimed to assess whether 
direct expression of the protein in vitro was associated with alterations in levels of viral 
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promoter activity. Given that such changes should correspond with the ability of LUNA to 
augment viral gene expression, any resulting findings might explain how LUNA-mediated 
increases in virus gene expression could be mediated by the modulation of viral 
transcriptional output. Using a reporter assay system established in early myeloid cell lines, 
levels of activity from the promoters of two latency-associated viral genes, UL144 and LUNA, 
were measured in the context of transient expression of wild-type LUNA. In the presence of 
LUNA, both viral gene promoters showed a significant increase in activity, indicating that 
LUNA was able to exert a positive upregulatory effect on latent viral gene transcription, 
including positive autoregulation of its own promoter. This suggests that LUNA is able to 
augment latency-associated viral gene promoters in order to affect alterations in virus gene 
expression. Importantly, the finding that the LUNA promoter does not show a significant 
difference in activity following LUNA expression in PML-knockdown cells argues for the 
ability of LUNA to exert its effects through the disruption of ND10. Even in the absence of 
ND10, however, it is noteworthy that the UL144 promoter was responsive to LUNA 
expression, indicating that LUNA may also promote viral gene transcription via an alternative 
mechanism that does not necessarily involve ND10 targeting. Earlier investigations 
concerning the regulation of latency-associated viral gene expression revealed that the cellular 
transcription factor, GATA-2, is able to regulate the activity of both the LUNA and 
UL144 promoters to suggest a potential mechanism by which latent viral gene expression may 
be induced by the host, prior to any de novo viral protein synthesis. When both GATA-2 and 
LUNA were co-expressed in the above system, this was found to yield an additive effect on 
the LUNA promoter, as well as the UL144 promoter suggesting that these factors may 
cooperate to enhance LUNA and UL144 gene expression during latent infection. These 
factors also interact physically with one another, which may be important for enabling their 
combined effect upon viral promoter activity.  
 
In the penultimate investigatory chapter (Chapter 6), the capacity of LUNA to function as a 
viral transcriptional regulator was tested against its ability to act as a viral isopeptidase. In 
brief, the LUNA protein had been found to possess a putative active site that shared weak 
homology to a class of cellular enzymes involved in the ubiquitin-like modification of 
proteins (Poole et al. Under review). Here, it was shown that LUNA could participate in the 
related post-translational modification of SUMO, specifically, by deconjugating 
SUMO moieties from protein substrates (deSUMOylation). When the active site was mutated 
to create a catalytically defective LUNA mutant (LUNAg233c), subsequent transient 
transfection analysis in early myeloid cells revealed that the mutant failed to disrupt ND10, 
117 
indicating that the protease activity in question was required for LUNA to target ND10 for 
disruption. Notably, the expression of g233c was not associated with an increase in activity of 
latency-associated viral gene promoters relative to  wild-type LUNA expression, suggesting 
that the deSUMOylase function was also required for normal HCMV promoter activity. 
Consistent with this, primary myeloid cells infected with g233c-containing mutants (g233c) 
failed to efficiently express viral genes compared to wild-type phenotype controls, akin to that 
observed for LUNA knockout viruses. Combined, these findings are in keeping with the main 
hypothesis that the disruption of ND10 by LUNA is important for the regulation of viral gene 
expression. However, as alluded to earlier, some latency-associated viral genes appear to be 
regulated by other mechanisms irrespective of LUNA-mediated ND10 disruption. This is 
reflected by the fact that g233c expression in cells depleted of PML appears to result in an 
upregulation of viral UL144 promoter activity, but does not yield any effect on the LUNA 
promoter; however, additional analysis is required to establish whether these particular 
findings are statistically significant. 
 
In the final results chapter (Chapter 7), an investigation was performed to evaluate the impact 
of another potential regulator of HCMV latency, specifically, concerning a host-derived factor 
termed HUSH. Briefly, HUSH is a recently characterised chromatin-associated complex that 
is involved in transgene repression, where it mediates the spread of pre-existing 
heterochromatin
323
. Using latently infected CD34
+
 myeloid cells, the contribution of HUSH 
with respect to latency was determined by shRNA-mediated depletion. Following 
transduction of shRNA targeting HUSH component TASOR and the key effector SETDB, a 
small increase in IE gene-expressing foci was observed, suggesting a potential role for HUSH 
in regulating latent HCMV infection. However, subsequent analysis of the chromatin 
landscape revealed little, if no significant change in the levels of activatory or repressive 
histone modifications to indicate that HUSH is not likely to be important for the regulation of 
the viral MIEP during latency. The significance of this finding is made clear by the fact that 
levels of MIEP activity show no difference when HUSH components are depleted, unless the 
MIEP has been experimentally integrated into the host cell genome, a context that is not 
present under normal conditions of infection. While these do not appear to accommodate a 
role for HUSH in the maintenance of latency, it is possible that they may still play a role in 
regulating MIEP activity during latent infection and this should be investigated further. 
 
The general thesis presented in this dissertation is that HCMV promotes the disruption of 
ND10 structures, an intrinsic cellular defence mechanism, during latent infection, which as a 
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result, appears to enhance the activity of its own latency-associated transcriptional 
programme. The findings presented contribute further to the discussion that HCMV latency is 
a dynamic process, one composed of a series of regulatory interactions between the virus and 
host cell that lie apart from the necessary repression of lytic genes. When placed into a wider 
context, ND10 structures should continue to be regarded as fulfilling a potent antiviral role 
that specifically calls for their abrogation by HCMV
330
. As such, numerous studies have 
firmly established the capacity of ND10 to thwart robust viral replication through individual 
contributions made by their major constituent proteins, PML, hDaxx and Sp100, which 
function as host restriction factors
331
. Indeed, PML and Sp100 were recently shown to act as 
IFN-stimulated genes (ISGs) that become upregulated during HCMV infection, further 
indicating that enhancement of the presence of ND10 and its associated effects is likely to fall 
under the rubric of the host IFN antiviral response
332,333
. Consequently, it is unsurprising that 
during the early stages of lytic infection, a number of strategies are employed by the virus to 
counteract the restriction activity of ND10, with the viral proteins IE1 and pp71 serving key 
roles in this regard
181
. Yet, despite the ability of ND10 to suppress virus gene expression, it is 
noteworthy that a number of studies have indicated a lack of involvement of ND10 in the 
establishment of HCMV latency. Notably, in cellular settings of latent infection, hDaxx had 
previously been shown to contribute towards critical repression of the MIEP through the 
recruitment of HDACs
197
. However, in contrast, knockdown of hDaxx in undifferentiated 
NT2 cells was found not to be sufficient to trigger IE gene transcription
185
. Additionally, it 
was recently reported that depletion of each of the above ND10 components in 
undifferentiated THP-1 cells had no effect on IE gene expression; but, compared to control 
cells, did dramatically increase the efficacy of viral reactivation following differentiation
302
. 
Together, the above findings support the likelihood of ND10 playing a more prominent role in 
restricting lytic replication and reactivation, rather than supporting latency; though, they failed 
to bring into question the possibility of ND10 being targeted for disruption during the latent 
period itself and by extension their potential complicity in restricting latent carriage. Here, my 
study into the function of the latency-associated gene product, LUNA, sheds light on this 
specific issue, characterising the protein as a viral factor responsible for mediating such 
disruption during latent infection, similar to what has been observed in cases of lytic 
replication. One may therefore infer that HCMV has evolved to overcome ND10 as a blanket 
requirement for infection, since the virus possesses the means to disrupt these structures in the 
host cell irrespective of its level of permissiveness for viral replication. During latency 
specifically, the disruption of ND10 has been shown to be important for enabling          
latency-associated viral gene expression, as evidenced by reduced levels of UL138 and IE 
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mRNA detection from infected early myeloid cells when LUNA is either absent or mutated. 
In conjunction with this, decreases in the activities of latency-associated viral gene promoters, 
associated with corresponding changes in the surrounding epigenetic landscape, are also 
observed when LUNA is absent or mutated. Such findings are consistent with previous 
investigations into LUNA, which demonstrated its requirement for efficient expression of 




 cells, and additionally, show that even latency-
associated viral gene promoters are capable of undergoing dynamic changes in chromatin 
structure during the latent period
266,334
. Thus, the removal of ND10 carries implications in 
terms of supporting viral latency, but also promoting efficient viral reactivation, as has been 
recently demonstrated by Poole et al. (2018)
317
. Nonetheless, the fact that incoming 
herpesvirus genomes accumulate at the periphery or within the central core of ND10 at early 
times post-infection should not be discounted
179,180,335
. Of particular note is the observation 
that ND10 found associated with herpesvirus genomes do not represent pre-existing sites, but 
are likely newly assembled structures that become localised to viral DNA, which is in keeping 
with their ability to be co-regulated by host IFN immune responses
336
. Consequently, since 
LUNA must be expressed de novo to ensure disruption of ND10, and tegument pp71 protein 
is not present in the nucleus during latent infection, this leaves open the possibility that these 
structures are still able to impact on HCMV genomes, and hence contribute towards latency. 
In support of this, ND10 possess the capability to subject HCMV genomes to epigenetic 
mechanisms of transcriptional control, which may be linked to the formation of inactive 
chromatin over the MIEP during latent infection, also seen at the start of lytic infection
169,185
. 
However, further studies will be required to define the exact contribution of individual ND10 
proteins to this process and help establish a time frame of regulatory events following viral 
genome deposition and chromatinisation up to parental ND10 disruption. Here, it may be 
important to uncover the identities of the various chromatin remodelers that bind to the viral 
genome when ND10 components are either present or absent, as this may help to further 
evaluate their roles as key transcriptional regulatory effectors.  
 
Because the loss of ND10 suggests an absence of intrinsic transcriptional repressive activity, 
this naturally raises the question of what other mechanisms may contribute to the regulation 
of latency, but, more still, brings into mind the consequences of granting further licence for  
latency-associated gene expression within the latently infected cell. These considerations are 
in keeping with the viewpoint that HCMV latency should not be regarded as a period of viral 
quiescence, but rather one composed of an active, ongoing interplay between the host cell and 
virus
337
. To begin with, it is generally understood that the nuclear factor milieu within a given 
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cell type and stage of differential serves as the critical determinant of whether the viral MIEP 
exhibits an underlying repressive phenotype capable of supporting latency, which contrasts 
with the milieu of a terminally differentiated cell type that would shift the MIEP towards a 
constitutive de-repressed phenotype. This is consistent with the fact that the MIEP is known 
to possess binding sites for a range of host transcriptional repressors as well as 
activators
102,170
. In conjunction with the data described thus far, it is therefore plausible that 
the loss of ND10 would have no effect on the acquisition of repressed chromatin found 
around the MIEP, since the silencing would be dictated by other host mechanisms that take 
priority in the latently infected cell. Rather, it seems likely that ND10 acts as a second layer of 
repression that primarily functions in the context of lytic permissiveness, in which the MIEP 
would conform to an open, transcriptionally active state
170
. Moreover, viral latency-associated 
gene products are becoming increasingly recognised as contributing importantly to latency as 
well as other processes necessary to sustain effective latent carriage
338
. Notably, viral UL138 
has already been implicated in silencing IE gene expression during latency
339
. Additionally, 
viral US28 was recently shown to be expressed in latently infected monocytes, playing a role 
in attenuating cellular signalling pathways that was required for latency establishment
340
. 
Besides viral protein coding genes, however, viral non-coding RNAs (ncRNAs) are expressed 
during latent infection and may also act as important regulators of this process, particularly in 
regards to avoiding immune surveillance. For instance, a possible role has been suggested for 
miR-UL112-3p in downregulating IE1 gene expression, which could help prevent T cell 
recognition of latently infected cells
341,342
. Similarly, miR-UL148D-1 targets ACVR1B, part 
of the activin signalling axis, to limit cellular IL-6 secretion by infected monocytes
315
. 
Together, the expression of all these transcripts - along with their subsequent positive impact 
on latent infection – may be augmented by the ability of LUNA to upregulate                
latency-associated gene promoter activity. Here, LUNA could function either by abrogating 
the inhibitory effects of ND10, or possibly, by directly affecting the promoters responsible 
through an as yet unidentified mechanism. Nevertheless, given that the activities of only two 
candidate latency-associated viral gene promoters were assessed in this project, it is clear that 
further work on other latent gene promoters will need to be performed to determine the extent 
of the impact of LUNA. Yet, insofar as the latent targeting of ND10 by LUNA is concerned, 
this points to a legitimate causal explanation, so as to facilitate viral transcription conducive to 
latency. One final consideration is how LUNA becomes expressed in the first instance. As 
reported here and elsewhere is the finding that the HCMV LUNA promoter is responsive to 
the effects of GATA-2, which indicates that the virus is able to exploit host cellular 
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Turning more closely to the viral LUNA protein itself, the identification of its novel encoded 
deSUMOylase activity lends fresh perspective to its general functionality, and broadly, the 
manipulation of SUMO pathways by the virus. Now, for the first time, a putative mechanism 
of action may be ascribed to the protein by which it may target ND10 structures for 
disruption, thereby relieving the effects of host cell transcriptional repression in manner that is 
consistent with previously published attempts to characterise its function. Moreover, although 
a number of HCMV proteins have since been implicated in the exploitation of SUMO 
modification system, LUNA also serves as the first example of one that functions within the 
context of latency. Before this discovery, KSHV was the only human herpesvirus whose 
ability to modify host SUMOylation during latency was extensively researched. Here, the key 
master regulator of KSHV latency, LANA1, had previously been shown to interact with 
SUMO-2 in order to recruit the chromatin remodeler SUMO-2-modified KAP1 along with 
other proteins to silence lytic genes and maintain the viral episome
343
. In addition, another 
KSHV latency-associated protein, vIRF-3 (a viral analogue of host interferon regulatory 
factor 3) was found to block SUMO modification of Rb, p53 and p130 factors, involved in 
controlling host cell cycle progression, thereby indicating that the virus was able to affect 
specific SUMO-modified signals
344,345
. Specifically, HCMV LUNA has been shown to 
possess an isopeptidase activity that allows it cleave SUMO-2/3 moieties, although its overall 
enzymatic specificity remains unclear
317
. Thus, it will be interesting to further evaluate the 
effects of LUNA and its associated deSUMOylase activity on viral proteins, but also host 
ones too, not least as the study of SUMO-regulated pathways is becoming a rapidly 
developing topic within the herpesvirus field
173,346
. For instance, it has recently been reported 
that GATA-2 signalling is stabilised by deSUMOylation, which may account for its capacity 
to function cooperatively with LUNA in regards to regulating latency-associated gene 
transcription
347
. Moreover, structural analysis of the LUNA protein should be performed to 
help understand how the protein localises to putative targets and also clarify the precise 
structure of its active site. This carries obvious implications for the pharmaceutical 
development of novel compounds to specifically target and inhibit LUNA, as part of a wider 
therapeutic strategy. 
 
Overall, for the purposes of this dissertation, further work will need to be performed to 
determine the extent to which the transcription of latency-associated viral genes are affected 
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by the activities of LUNA. Notably, the repertoire of candidate latency-associated viral gene 
promoters for interrogation requires expansion. In addition, further evidence of PML 
disruption should be gathered in order to more directly attribute changes in gene expression to 
loss of ND10 and, in turn, LUNA expression. This could be achieved by immunoblotting for 
SUMO-modified PML to detect loss of high molecular weight PML species. Most 
importantly, it will be worthwhile employing the use of some alternative means of inhibiting 
the deSUMOylase activity of LUNA, for instance, by making use of currently available 
pharmacological agents (e.g. pan-isopeptidase inhibitors), to strengthen not only the key 
hypothesis that part of the ability of LUNA to regulate latent gene transcription is dependent 
on its enzymatic activity, but also determine whether disabling the function of LUNA could 
prevent the virus from establishing and maintaining a successful latent infection, thereby, 
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